{"Title": ["3 Biotech Stocks I\u2019d Buy Right Now", "Analysts Predict 10% Gains Ahead For The Holdings of MDY", "How Biotech Companies Are Valued", "We Did The Math IWR Can Go To $56", "Interesting EXEL Put And Call Options For July 17th", "Better Buy: bluebird bio vs. Exelixis", "Exelixis Inc (EXEL) Q1 2020 Earnings Call Transcript", "USO, IDNA: Big ETF Inflows", "3 Biotech Stocks I\u2019d Buy Right Now", "Better Buy: AnaptysBio vs. Exelixis", "Exelixis Reaches Analyst Target Price", "CYCC In STOPCOVID, EXEL Hits New High, NVS Trialing Malaria Drug For COVID-19", "Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials", "BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma", "BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group", "Why Exelixis Stock Is Skyrocketing Today", "First Trust NYSE Arca Biotechnology Index Fund Experiences Big Inflow", "Have $5,000? Then Buy These Top Stocks on Any Coronavirus Weakness", "2 Biotechs Battling Against Kidney Cancer", "Is Exelixis a Buy?", "Have An Extra $1,000? Buy These 2 Biotech Stocks", "2 Cancer Stocks That Could Make You Filthy Rich", "3 Top Stocks That Will Make You Richer in Q2 (and Beyond)", "Interesting EXEL Put And Call Options For November 20th", "Bristol Myers says Opdivo performs well in kidney, lung cancer trials", "Coronavirus Crisis: 3 Biotech Stocks to Buy Right Now", "3 Cancer Treatment Stocks to Buy Right Now", "Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday", "Here's Why NuVasive, Exelixis, and Natus Medical Fell Today", "6 Quality Biotech Stocks on Sale Now", "3 Biotech Stocks That Are Coronavirus Safe Havens", "EXEL Crosses Above Key Moving Average Level", "Have $2,500? Then Buy These 4 Cash-Rich Stocks Now", "Exelixis Inc (EXEL) Q4 2019 Earnings Call Transcript", "Validea's Top Five Healthcare Stocks Based On David Dreman - 2/16/2020", "3 Mid-Cap Growth Stocks to Buy", "Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study", "3 Stocks I'll Never Sell", "3 Cancer Treatment Stocks to Buy Right Now", "Interesting EXEL Put And Call Options For June 19th", "Investors Endure Wild Ride in This Biotech Taking on COVID-19", "Validea's Top Five Healthcare Stocks Based On David Dreman - 1/19/2020", "5 Mid-Cap Stocks You'll Want to Own in 2020", "Bullish Two Hundred Day Moving Average Cross - EXEL", "5 Value Stocks That Will Make You Richer in 2020", "10 Top Stocks That Will Make You Richer in 2020", "Interesting EXEL Put And Call Options For August 2020", "Can Investors Excel in 2020 With Exelixis?", "Validea's Top Five Healthcare Stocks Based On David Dreman - 12/15/2019", "Health Care Sector Update for 12/13/2019: SRPT, BLRX, EXEL, JNJ, PFE, ABT, MRK, AMGN", "3 Top Growth Stocks to Buy in December", "Why Did Farallon Capital Get Out of These 3 Biotech Stocks?", "3 Stocks Peter Lynch Would Love", "Exelixis\u2019 Stock Regains Its Mojo", "Why Exelixis Stock Broke Down in October", "2 Incredibly Cheap Biotech Stocks", "Here\u2019s Why Exelexis Sank Today", "Exelixis Inc (EXEL) Q3 2019 Earnings Call Transcript", "7 Under-The-Radar Growth Stocks That Could Benefit New Investors", "Will The Pace of M&A Pick Up Following The Biotech Sector\u2019s Pounding?", "3 Mid-Cap Biotech Stocks To Consider Buying Now", "Interesting EXEL Put And Call Options For January 2022", "Implied USEQ Analyst Target Price: $31", "20 Stocks That Could Double Your Money in 2020", "Notable Friday Option Activity: EXEL, IIPR, TEAM", "3 Cancer Treatment Stocks to Buy Right Now", "10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar", "First Week of EXEL September 20th Options Trading", "Exelixis Hits Blockbuster Status", "Notable Two Hundred Day Moving Average Cross - EXEL", "Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript", "Wednesday's ETF Movers: OIH, FBT", "10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar", "Notable Two Hundred Day Moving Average Cross - EXEL", "Is Exelixis a Buy?", "3 Cancer-Treatment Stocks to Buy", "First Week of February 2020 Options Trading For Exelixis (EXEL)", "Read This Before You Buy Any New Cancer Drug Stocks", "Oh, By the Way, This Clinical Trial Didn't Work", "3 Cancer Treatment Stocks to Buy Right Now", "Top 5 Stocks in the Fight Against Cancer", "Analysts Predict 17% Upside For PWC", "EXEL Crosses Above Key Moving Average Level", "These 3 Value Stocks Are Absurdly Cheap Right Now", "Where Will Gilead Sciences Spend Its Cash?", "Exelixis Inc (EXEL) Q1 2019 Earnings Call Transcript", "2 Incredibly Cheap Value Stocks to Buy Now", "Exelixis (EXEL) Shares Cross Above 200 DMA", "Top 5 Stocks in the Fight Against Cancer", "Analysts Predict 17% Upside For PWC", "3 Cancer Treatment Stocks to Buy in April", "5 Top Pharmaceutical Stocks to Buy in 2019", "5 Top Biotech Stocks to Buy in 2019", "Exelixis is Now Oversold (EXEL)", "ProQR Initiates Dosing in Phase II/III Eye Disorder Study", "Health Care Sector Update for 04/25/2019: WST,BMY,EXEL,ALKS", "First Week of EXEL November 15th Options Trading", "8 Stocks to Buy That Are Growing Faster Than Amazon", "Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?", "After Hours Most Active for Apr 3, 2019 : CMCSA, BBD, PARR, BAC, CNHI, EBAY, MSFT, UAL, AES, SYF, ACHC, EXEL", "Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?", "Exelixis (EXEL) Gains As Market Dips: What You Should Know", "Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation", "Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock", "3 Best Biotech Bargain Stocks on the Market Right Now", "Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster", "Tuesday's ETF with Unusual Volume: PBE", "Validea's Top Five Healthcare Stocks Based On David Dreman - 2/17/2019", "New Strong Sell Stocks for February 15th", "Implied Volatility Surging for Exelixis (EXEL) Stock Options", "Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN", "Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know", "Exelixis Grabs 90% of First Place", "Health Care Sector Update for 02/13/2019: TEVA,EXEL,BABY", "Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4", "Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript", "Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates", "After-Hours Earnings Report for February 12, 2019 : OXY, ATVI, ACGL, UDR, AKAM, TWLO, TRIP, BFAM, HUBS, DEI, EXEL, AIZ", "Earnings Reaction History: Exelixis, Inc., 75.0% Follow-Through Indicator, 8.7% Sensitive", "Health Care Sector Update for 02/13/2019: CRL,TEVA,EXEL,BABY", "8 Stocks to Buy That Are Growing Faster Than Amazon", "Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?", "How The Pieces Add Up: ONEO Headed For $77", "Exelixis (EXEL) Stock Sinks As Market Gains: What You Should Know", "Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod", "Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer", "5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019", "Notable Friday Option Activity: CYH, EXEL, UBNT", "8 Stocks to Buy That Are Growing Faster Than Amazon", "Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?", "Health Care Sector Update for 01/08/2019: EXEL,AXSM,AKRX", "After Hours Most Active for Jan 4, 2019 : QQQ, GE, TRCO, FRC, INFO, OAS, EQT, YELP, GOGO, EXEL, FB, SSNC", "EXEL Makes Bullish Cross Above Critical Moving Average", "Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure", "The Math Shows ONEO Can Go To $82", "Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know", "3 Biotechs Gilead Sciences Could Buy in March", "5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride", "The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis", "Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate", "Here's Why Exelixis Stock Jumped 46.4% in November", "Why Exelixis (EXEL) Could Be Positioned for a Surge", "Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report?", "5 Excellent GARP Picks With Cheap PEG Ratio", "3 Top Growth Stocks to Buy Right Now", "Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss", "Sarepta Stock More Than Doubles This Year So Far: Here's Why", "Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx", "Health Care Sector Update for 11/15/2018: QURE, EXEL, AVEO, JNJ, PFE, MRK, ABT, AMGN", "Can Exelixis (EXEL) Run Higher on Rising Earnings Estimates?", "Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market", "EXEL Makes Bullish Cross Above Critical Moving Average", "3 Top Growth Stocks to Buy Right Now", "Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss", "Sarepta Stock More Than Doubles This Year So Far: Here's Why", "Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx", "Exelixis (EXEL) to Report Q3 Earnings: What's in Store?", "Why Merck's Latest Success Means Trouble for Exelixis Inc.", "Exelixis Inc (EXEL) Q3 2018 Earnings Conference Call Transcript", "Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)", "3 Top Mid-Cap Stocks to Buy in October", "8 Stocks to Buy That Are Growing Faster Than Amazon", "First Week of EXEL May 2019 Options Trading", "Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx", "3 Top Biotech Stocks to Buy Right Now", "Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada", "5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage", "Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)", "3 Top Mid-Cap Stocks to Buy in October", "Exelixis' Cabometyx Recommended by NCCN for All Types of RCC", "3 Monster Biotech Stocks in the Making", "Exelixis (EXEL) Down 14.1% Since Last Earnings Report: Can It Rebound?", "3 Stocks That Could Put Apple's Returns to Shame", "7 Biotech Stocks to Buy Now", "Relative Strength Alert For Exelixis", "8 Undervalued Biotech Stocks to Watch", "Monday Sector Laggards: Biotechnology, Drugs", "Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation", "13 of the Cheapest Healthcare Stocks", "Exelixis Gets the Patients Eventually", "Here's Why Exelixis Stock Jumped Higher Today", "Is Beaten-Down Exelixis, Inc. a Buy Now?", "Is Exelixis (EXEL) Poised for a Beat Again in Q2?", "Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc.", "Roche's Tecentriq Gets Breakthrough Therapy Status for HCC", "After Hours Most Active for Jul 10, 2018 : CUZ, KKR, GLPI, TWTR, MRVL, FDC, QQQ, PFE, INTC, BAC, EXEL, VC", "After Hours Most Active for Jun 29, 2018 : CPRT, EXEL, DPS, CMCSA, TWTR, UPL, GE, QQQ, SYMC, EXC, BAC, GM", "3 Top Healthcare Stocks to Buy Right Now", "Exelixis (EXEL) Jumps: Stock Rises 8%", "3 Top Mid-Cap Stocks to Buy Right Now", "ASCO Conference Preview: Here's What Biotech Investors Need to Watch", "Interesting EXEL Put And Call Options For July 20th", "Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx", "3 Top Biotech Stocks to Buy Right Now", "Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer", "Here's Why You Should Sell Fresenius Medical (FMS) Stock Now", "Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss", "Better Buy: Exelixis, Inc. vs. Immunogen, Inc.", "ASCO Conference Preview: Here's What Biotech Investors Need to Watch", "Interesting EXEL Put And Call Options For July 20th", "Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter", "3 Healthcare Stocks Growing Over 100%", "Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.", "Bull of the Day: Exelixis (EXEL)", "Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day", "Here's Why You Should Invest in Intuitive Surgical Right Now", "5 Winning Stocks With Superb Efficiency Level", "Pre-Market Most Active for May 10, 2018 : NBR, ROKU, BP, TVIX, QQQ, WFC, HEAR, AEG, CHL, EXEL, NVDA, ING", "Why Booking Holdings, Exelixis, and L Brands Slumped Today", "Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings", "Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View", "Why Exelixis Dropped Today", "Dow Moves Back in the Black for 2018", "Here's Why You Should Invest in Intuitive Surgical Right Now", "5 Winning Stocks With Superb Efficiency Level", "Pre-Market Most Active for May 10, 2018 : NBR, ROKU, BP, TVIX, QQQ, WFC, HEAR, AEG, CHL, EXEL, NVDA, ING", "Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag", "Exelixis Reaccelerates Growth", "Notable Friday Option Activity: GILD, EXEL, RIG", "Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength", "Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings", "Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected", "Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss", "No Deal? No Problem for the Market", "Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher", "After Hours Most Active for Apr 10, 2018 : CMCSA, KMI, IP, QQQ, CZR, HRB, PAA, YEXT, BX, INTC, EXEL, AKRX", "Moving Average Crossover Alert: Exelixis, Inc. (EXEL)", "Better Buy: Exelixis, Inc. vs. Novartis AG", "Exelixis (EXEL) Q1 2018 Earnings Conference Call Transcript", "Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings?", "Calithera's Kidney Cancer Candidate Gets Fast Track Status", "Why Exelixis' Stock Broke Down in March", "Commit To Purchase Exelixis At $13, Earn 11.2% Using Options", "After Hours Most Active for Mar 14, 2018 : QQQ, FOLD, F, MSFT, QEP, GM, USMC, BEN, CMCSA, BSX, CNP, EXEL", "Why Exelixis Fell 14.9% in February", "3 Top Biotech Stocks to Buy in April", "Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?", "Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?", "Exelixis Cabometyx Gets Positive CHMP Opinion in Europe", "RSI Alert: Exelixis (EXEL) Now Oversold", "Commit To Purchase Exelixis At $13, Earn 11.2% Using Options", "3 Stocks to Watch on Tuesday: Exelixis, Inc. (EXEL), Howard Hughes Corp (HHC) and Palo Alto Networks Inc (PANW)", "Exelixis Becomes Oversold", "Exelixis Breaks Below 200-Day Moving Average - Notable for EXEL", "Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down", "Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat", "Health Care Sector Update for 02/27/2018: MNK, IART, AMRN, PRGO. EXEL", "Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4", "5 Things Exelixis Inc. Management Wants You to Know About the Biotech's Future", "3 Stocks to Watch on Tuesday: Exelixis, Inc. (EXEL), Howard Hughes Corp (HHC) and Palo Alto Networks Inc (PANW)", "Exelixis Becomes Oversold", "Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)", "Exelixis Inc. (EXEL) Q4 2017 Earnings Conference Call Transcript", "Key Factors to Influence Penumbra's (PEN) Earnings in Q4", "What's in Store for Veeva Systems (VEEV) in Q4 Earnings?", "Is a Beat in Store for Inogen (INGN) This Earnings Season?", "What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?", "Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y", "What to Expect From BioMarin (BMRN) This Earnings Season?", "What's in the Cards for Geron (GERN) This Earnings Season?", "Novartis Psoriasis Drug Cosentyx Positive in SCALP Study", "Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?", "What's in Store for Ligand (LGND) This Earnings Season?", "AbbVie Presents New Data on Upadacitinib for Crohn's Disease", "Celgene Reports Positive Data on Dermatology Drug Otezla", "Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?", "Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion", "Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb", "Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View", "Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y", "Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses", "Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong", "Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva", "Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat", "Can CVG Boost Medtronic's (MDT) Q3 Earnings Once Again?", "Roche's Rituxan Gets Priority Review for Label Expansion", "AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda", "Exelixis Reports Positive Data From Thyroid Carcinoma Trial", "Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval", "Intercept Starts OCA Trial for NASH Patients With Cirrhosis", "Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates", "Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?", "Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?", "FDA Okays J&J's Prostate Cancer Drug in First-Line Setting", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates", "Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?", "Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?", "Shire (SHPG) to Report Q4 Earnings: What's in the Cards?", "Theravance, J&J Ink Deal for Inflammatory Intestinal Drug", "Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4", "Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down", "Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural", "Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study", "Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study", "Pfizer Files for Xtandi in Early Stage Prostate Cancer", "Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow", "5 of the Best Efficient Stocks for Your Portfolio", "5 Biotech Stocks Set to Trump Estimates This Earnings Season", "Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?", "Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Strength Seen in Alkermes (ALKS): Stock Soars 8.7%", "Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod", "Roche Reports Positive Data From Tecentriq-Avastin Study", "Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review", "Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?", "Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?", "Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa", "Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat", "Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label", "Puma & Medison Team Up to Commercialize Nerlynx in Israel", "Puma, CANbridge Team Up to Commercialize Nerlynx in China", "Roche Gets Breakthrough Therapy Designation For ASD Drug", "Rough Start to Busy Week", "Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?", "Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion", "Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat", "Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why", "What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?", "The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ", "EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down", "Anthera's Sollpura Strong on Positive Futility in Phase III", "Seattle Genetics' Adcetris Gets EU Nod for Label Expansion", "Regeneron's Dupixent Receives MHLW Nod for Label Expansion", "BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall", "Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y", "Shire Gets FDA Nod for Cinryze Tech Transfer to New Site", "The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ", "Bristol-Myers (BMY) Reports Data from CheckMate-142 Study", "These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition", "Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year", "BeiGene (BGNE) Surges: Stock Moves 12.6% Higher", "BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa", "Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks", "Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?", "Exelixis, Ipsen Report Positive Results on Lead Cancer Drug", "Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results", "Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?", "Novartis (NVS) Announces Acceptance of Humira BLA by the FDA", "Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion", "Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?", "Merck Strong on Confirmatory Phase III Lung Cancer Study", "Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?", "Exelixis, Ipsen Report Positive Results on Lead Cancer Drug", "Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results", "Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018?", "Novartis (NVS) Announces Acceptance of Humira BLA by the FDA", "Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion", "Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?", "Merck Strong on Confirmatory Phase III Lung Cancer Study", "Aradigm's Bronchiectasis Candidate Has Negative FDA Vote", "Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?", "The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex", "Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod", "Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse", "Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%", "Emergent Down on '18 View, Posts Preliminary '17 Results", "Why is Novo Nordisk Stock Up More Than 50% in Past Year?", "4 Reasons Exelixis, Inc. More Than Doubled in 2017", "Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales", "Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home", "Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up", "Novo Nordisk Confirms Bid for Ablynx But Faces Rejection", "Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%", "Emergent Down on '18 View, Posts Preliminary '17 Results", "Why is Novo Nordisk Stock Up More Than 50% in Past Year?", "Alnylam, Sanofi Announce Restructuring Deal for RNAi Products", "The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines", "Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma", "Cancer Space Update: New Regulatory Status for 3 Major Drugs", "Emergent Starts Phase II Study on Anti-influenza Candidate", "4 Biotech Stocks to Watch in the New Year", "Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial", "Acorda's Shares Down on Disappointing Ampyra View for 2018", "Pfizer (PFE) Collaborates With Sangamo for Gene Therapy", "The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December", "Inovio Amends Chinese Deal for Immunotherapy, Shares Up", "Valeant (VRX) to Settle Allergan Litigation for $290 Million", "Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?", "8 Stocks to Buy That Are Growing Faster Than Amazon", "Stocks Showing Market Leadership: Exelixis Earns 93 RS Rating", "United Therapeutics (UTHR) Collaborates With Corsair Pharma", "Christmas Comes Early For These 5 Biotechnology Stocks", "Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors", "Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer", "Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy", "Stocks Showing Improving Market Leadership: Exelixis Earns 83 RS Rating", "Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer", "Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run", "If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One", "Christmas Comes Early For These 5 Biotechnology Stocks", "Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors", "Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer", "Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy", "Stocks Showing Improving Market Leadership: Exelixis Earns 83 RS Rating", "Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer", "Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run", "If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One", "Christmas Comes Early For These 5 Biotechnology Stocks", "Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors", "Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up", "Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up", "Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates", "Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3", "VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down", "Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms", "Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut", "Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up", "Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag", "Infinity (INFI) Q3 Loss Narrower than Expected, View Intact", "AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda", "Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss", "Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus", "3 Reasons Behind Exelixis Stock's Big Bounce", "Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus", "Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat", "The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%", "Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views", "Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y", "If Celgene Buys This Biotech, Investors Should Win Big-Time", "Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales", "Add Up The Pieces: FXH Could Be Worth $75", "What's in the Offing for Exelixis (EXEL) in Q3 Earnings?", "Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus", "3 Top Biotech Stocks to Buy Now", "Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.", "Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug", "Company News For Oct 17, 2017", "Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong", "Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session", "Why Exelixis' Rebound Is Just Getting Started", "Exelixis Earns Relative Strength Rating Upgrade", "Health Care Sector Update for 10/16/2017: AMPE,EXEL,TGTX", "Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline", "Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views", "Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News", "FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx", "Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session", "Why Exelixis' Rebound Is Just Getting Started", "Exelixis Earns Relative Strength Rating Upgrade", "Monday's ETF with Unusual Volume: PDP", "Monday's ETF Movers: PDP, XRT", "Rhenman & Partners Asset Management AB Buys Arena Pharmaceuticals Inc, Vertex ...", "The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September", "Pre-Market Most Active for Oct 16, 2017 : F, EXEL, GSK, VALE, NVO, BAC, JD, MNKD, TEVA, AAPL, MU, XT", "3 Beaten-Down Biotech Stocks to Buy Right Now", "Better Buy: Exelixis, Inc. vs. Immunogen, Inc.", "XBI, CLVS, EXEL, SRPT: Large Outflows Detected at ETF", "3 Reasons to Buy the Dip With Exelixis", "Look Under The Hood: FXH Has 10% Upside", "Relative Strength Alert For Exelixis", "3 Monster Biotech Stocks in the Making", "Why These Biotechs Are Leading The Group Near A 21-Month High", "Why Exelixis, Inc. Slumped Today", "Why Exelixis Wouldn't Be a Warren Buffett Stock", "SPDR S&P Biotech ETF Experiences Big Outflow", "Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?", "Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $8.1 million of Shares", "Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale", "Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors", "These 3 Stocks Are Priced for Perfection. Can They Deliver?", "Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock", "Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD", "Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?", "XBI, EXEL, ALXN, VRTX: ETF Inflow Alert", "Can Buying Exelixis Stock Still Make You Rich?", "4 of the Highest-Growth Stocks in Biotech Today", "Noteworthy ETF Inflows: XBI, EXEL, ALXN, VRTX", "2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August", "Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock", "Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD", "Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?", "Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts", "Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag", "AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2", "Surprising Analyst 12-Month Target For FXH", "Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx", "Why Gilead Sciences Might Not Make an Oncology Acquisition", "Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales", "3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance", "Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised", "Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2", "Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass", "Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise", "ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up", "Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat", "Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat", "Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line", "Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View", "GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance", "Commit To Buy Exelixis At $17, Earn 11.5% Using Options", "Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up", "XBI, CLVS, EXEL, ALXN: ETF Outflow Alert", "What's in the Cards for Exelixis (EXEL) in Q2 Earnings?", "2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't", "PGX, PTH: Big ETF Inflows", "Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab", "Vertex (VRTX) Triple Combination CF Studies Data Positive", "Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View", "Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up", "XBI, CLVS, EXEL, ALXN: ETF Outflow Alert", "What's in the Cards for Exelixis (EXEL) in Q2 Earnings?", "2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't", "PGX, PTH: Big ETF Inflows", "Exelixis Reaches Analyst Target Price", "Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt", "Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?", "BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug", "Arena Announces Secondary Stock Offering of 150M Shares", "Five Scorching Hot Stocks Screaming Higher", "Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx", "This Biotech Finds Its Stride With Kidney Cancer Treatment", "The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32%", "Why Exelixis (EXEL) Could Be an Impressive Growth Stock", "3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates", "Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN", "The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners", "Best Stocks For The Second Half of 2017", "SPDR S&P Biotech ETF Experiences Big Inflow", "Top Ranked Momentum Stocks to Buy for June 27th", "AVEO's Kidney Cancer Candidate Gets CHMP Recommendation", "After Hours Most Active for Jul 6, 2017 : WY, PHM, OKE, MRK, QQQ, SRC, APC, TTWO, AAPL, ATVI, EXEL, CSCO", "These 3 Stocks Are Up Over 500% in the Last 3 Years", "Better Buy: Exelixis, Inc. vs. Novartis AG", "Roundtable: 1 Stock I Brag About Owning", "After Hours Most Active for Jun 23, 2017 : EXEL, EBAY, AVP, FNB, GRPN, BGCP, NRZ, CVS, MU, ESV, BMY, AAPL", "Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide", "AVEO Reaches Enrollment Target in Pivotal Tivozanib Study", "Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations", "Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session", "2 Longs And 2 Shorts to Watch: June 21", "Exelixis's Cabometyx Positive for First-Line Kidney Cancer", "Why Exelixis, Inc. Zoomed Higher Today", "Monday Sector Leaders: Medical Instruments & Supplies, Biotechnology Stocks", "Exelixis Initiates Cabozantinib-Tecentriq Combination Trial", "2 Reasons Exelixis, Inc. Shares Sank 16% in May", "3 Stocks With Exelixis-Like Return Potential", "Noteworthy Wednesday Option Activity: ACIA, EXEL, ULTA", "2 Longs And 2 Shorts to Watch: June 21", "Exelixis's Cabometyx Positive for First-Line Kidney Cancer", "Why Exelixis, Inc. Zoomed Higher Today", "5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know", "Five Breakout Zacks Rank #1 (Strong Buy) Stocks on the Move", "Play Potential Earnings Beat with These 5 Top-Ranked Stocks", "Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU", "Whoa, an Operating Profit for Exelixis, Inc.", "Interesting EXEL Put And Call Options For June 16th", "Earnings Reaction History: Exelixis, Inc., 60.0% Follow-Through Indicator, 7.5% Sensitive", "5 Things Bristol-Myers Squibb's Management Wants You to Know", "Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?", "Is Intercept (ICPT) Poised for a Beat This Earnings Season?", "What to Expect from Quotient Technology (QUOT) Q1 Earnings?", "Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus", "Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?", "Meditor Group Ltd Buys Celldex Therapeutics, Sells VIVUS", "Read This Before You Buy Biotech Stocks", "Here's Why the Best Is Yet to Come for Exelixis, Inc.", "XBI, VRTX, BIVV, EXEL: Large Inflows Detected at ETF", "Exelixis, Inc.: Time to Move On?", "3 Stocks That Turned $5,000 Into More Than $18,000 in a Year or Less", "Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?", "Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?", "Meditor Group Ltd Buys Celldex Therapeutics, Sells VIVUS", "Read This Before You Buy Biotech Stocks", "Here's Why the Best Is Yet to Come for Exelixis, Inc.", "XBI, VRTX, BIVV, EXEL: Large Inflows Detected at ETF", "Exelixis, Inc.: Time to Move On?", "3 Stocks That Turned $5,000 Into More Than $18,000 in a Year or Less", "Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?", "Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?", "Meditor Group Ltd Buys Celldex Therapeutics, Sells VIVUS", "Read This Before You Buy Biotech Stocks", "Here's Why the Best Is Yet to Come for Exelixis, Inc.", "XBI, VRTX, BIVV, EXEL: Large Inflows Detected at ETF", "Exelixis, Inc.: Time to Move On?", "3 Stocks That Turned $5,000 Into More Than $18,000 in a Year or Less", "XLF, PTH: Big ETF Outflows", "If You Love Exelixis, You Should Check Out Juno Therapeutics", "3 Winning Stocks You Never Saw Coming", "IWM, AMD, EXEL, NRZ: Large Inflows Detected at ETF", "Why Exelixis Is Already Up 55% This Year", "The 3 Most Important Numbers for Exelixis, Inc.", "Top Stocks That Are Already Crushing the Market in 2017", "3 Horrible Stocks for Retirees", "XLF, PTH: Big ETF Outflows", "Is Exelixis' Balance Sheet Safe?", "9 Stocks to Buy That Are Growing Faster Than Amazon", "Noteworthy ETF Outflows: UWM, NRZ, XPO, EXEL", "Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis", "Exelixis, Inc. Turns a Profit, but Don't Get Too Excited", "Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y", "Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC", "3 Factors That Drove Exelixis, Inc. Higher By 19% in February", "Keryx (KERX) Q4 Earnings: What's in Store for the Stock?", "Radius Health (RDUS) Posts Wider Loss in Q4", "TriMas (TRS) to Post Q4 Earnings: What's in the Cards?", "Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?", "Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?", "Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?", "Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?", "Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?", "Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?", "Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?", "First Week of EXEL April 21st Options Trading", "Patterson Companies (PDCO) Q3 Earnings: What's in Store?", "Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?", "Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?", "ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?", "Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?", "BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?", "Merrimack (MACK): What Awaits the Stock in Q4 Earnings?", "Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?", "The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics", "Forget Gilead, Buy These 5 Biotech Stocks Instead", "5 Drug Stocks Poised to Beat Earnings Estimates in Q4", "Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb", "Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?", "Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors", "Exelixis (EXEL) Shares March Higher, Can It Continue?", "Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?", "Ecolab (ECL): What's in the Cards this Earnings Season?", "Buy 4 Stocks Riding High on Superb Earnings Acceleration", "5 Drug Stocks Poised to Beat Earnings Estimates in Q4", "Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb", "The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals", "The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma", "3 Scorching Hot Biotech Stocks -- Are They Buys?", "4 Stocks to Watch, Led by Biotech", "4 Drug Stocks that are Broker Favorites", "5 Great Biotech Stocks to Buy Now", "2 Big Reasons Exelixis, Inc. Soared 22% in January", "DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?", "The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals", "The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma", "3 Scorching Hot Biotech Stocks -- Are They Buys?", "4 Stocks to Watch, Led by Biotech", "4 Drug Stocks that are Broker Favorites", "5 Great Biotech Stocks to Buy Now", "2 Big Reasons Exelixis, Inc. Soared 22% in January", "DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?", "3 Mid-Cap Biotech Stocks to Buy in February", "Better Buy: Exelixis, Inc. vs. Novartis", "4 Momentum Charts to Watch This Week", "After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next", "The 3 Biggest Risks for Pfizer in 2017", "The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen", "Better Buy: Celldex Therapeutics, Inc. vs. Exelixis", "The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016", "Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx", "Interesting EXEL Put And Call Options For August 2017", "Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead?", "7 Top Stocks We're Excited About Headed Into 2017", "Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead", "XT, EXEL, S, MRVL: Large Inflows Detected at ETF", "The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis", "4 Biotech Stocks that More than Doubled in 2016", "2 Companies I Wish I'd Bought in 2016", "Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite", "Wednesday's ETF Movers: GDXJ, XBI", "Wednesday Sector Laggards: Drugs, Biotechnology Stocks", "Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide", "Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults", "3 Biotech Stocks to Buy in December", "5 Top Performing Biotechnology Stocks of November", "7 A-Rated Healthcare Stocks to Buy Before Trump Takes Office", "Shire Launches Cuvitru in U.S. for Primary Immunodeficiency", "3 Things Exelixis Must Do to Survive and Thrive in 2017", "3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise", "Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration", "New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day", "Endo Reports Positive Cellulite Treatment Data on Xiaflex", "Is Exelixis the Best Small-Cap Biotech Stock?", "7 A-Rated Healthcare Stocks to Buy Before Trump Takes Office", "Shire Launches Cuvitru in U.S. for Primary Immunodeficiency", "3 Things Exelixis Must Do to Survive and Thrive in 2017", "3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise", "Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration", "New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day", "Ionis (IONS) Offers Positive Interim Data on Lipid Candidate", "Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz", "Celldex Stock Up on Positive Data on New Cancer Candidate", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3", "Mylan (MYL) Q3 Earnings & Revenues Miss on EpiPen Woes", "VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3", "Election 2016's Healthcare Winners and Losers", "The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte", "Endo (ENDP) Q3 Earnings & Revenues Beat; View Intact", "Wright Medical (WMGI) Q3 Loss Narrower than Expected", "Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise", "Horizon (HZNP) Stock Up Despite Q3 Earnings, Revenue Miss", "Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3", "Pacific Biosciences (PACB) Q3 Loss Narrower than Expected", "Masimo (MASI) Beats on Q3 Earnings, Revenues; Guides Up", "Exelixis, Inc. Continues Its Solid Launch", "Why We're Excited About These 5 Top Stocks", "DENTSPLY (XRAY) Beats on Earnings in Q3, Misses Revenue", "Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss", "Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3", "2 Reasons Exelixis, Inc. Dove 17% in October, and 1 Excuse to Be Excited", "Pacific Biosciences (PACB) Q3 Loss Narrower than Expected", "Masimo (MASI) Beats on Q3 Earnings, Revenues; Guides Up", "Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y", "Community Health (CYH) Q3 Loss in Line with Estimates", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3", "Why Exelixis, Inc. Reported Higher Today", "Friday's ETF Movers: XBI, GDXJ", "Acadia Healthcare (ACHC) Misses Q3 Earnings, Cuts View", "Aduro (ADRO) Stock Down on Wider-than-Expected Q3 Loss", "Geron (GERN) Reports Narrower-than-Expected Loss in Q3", "Radius Health (RDUS) Q3 Loss Match Estimates, Wider Y/Y", "Community Health (CYH) Q3 Loss in Line with Estimates", "AmerisourceBergen (ABC) Q4 Earnings Top, Revenues Lag", "QLT's (QLTI) Reports In-Line Q3 Loss, Merger in Focus", "Gilead (GILD) Misses Q3 Earnings Estimates, Retains View", "Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus", "Prothena (PRTA) Reports Wider-than-Expected Loss in Q3", "Shire (SHPG) Misses Q3 Earnings & Revenue Estimates", "Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX", "Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y", "ImmunoGen (IMGN) Reports Wider-than-Expected Loss", "Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?", "AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates", "Zoetis (ZTS) Tops Q3 Earnings Estimates, Updates Outlook", "Prothena (PRTA) Reports Wider-than-Expected Loss in Q3", "Shire (SHPG) Misses Q3 Earnings & Revenue Estimates", "McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View", "Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook", "The Medicines Co. (MDCO) Q3 Loss Narrower than Expected", "Cardinal Health (CAH) Q1 Earnings: Disappointment in Store?", "Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners", "BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus", "Vertex's (VRTX) Q3 Loss Wider than Expected, Sales Miss", "Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View", "Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts", "5 Profitable Stocks for Outstanding Returns", "Aduro Stock Down on Partial Clinical Hold on LADD Studies", "Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study", "What's in Store for Stryker (SYK) this Earnings Season?", "Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag", "Vertex's (VRTX) Q3 Loss Wider than Expected, Sales Miss", "Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View", "Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts", "5 Profitable Stocks for Outstanding Returns", "Aduro Stock Down on Partial Clinical Hold on LADD Studies", "Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study", "What's in Store for Merit Medical (MMSI) in Q3 Earnings?", "Ligand Partner Melinta Therapeutics Submits NDA for Baxdela", "Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?", "Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA", "Merck Gets FDA Approval for Investigational Drug Zinplava", "United Health (UHS): What's in Store this Earnings Season?", "Varian Medical (VAR) Q4 Earnings: What's in the Cards?", "C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?", "What's in Store for Merit Medical (MMSI) in Q3 Earnings?", "XBI's Underlying Holdings Could Mean 43% Gain Potential", "Alkermes Depression Candidate Positive in Phase III Study", "Alexion Graft-Versus-Host Disease Drug Wins Orphan Status", "Merck's Antiviral Medicine Meets Endpoint in Phase III", "Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma", "AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted", "What's in Store for athenahealth (ATHN) in Q3 Earnings?", "Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study", "XBI's Underlying Holdings Could Mean 43% Gain Potential", "Alkermes Depression Candidate Positive in Phase III Study", "Alexion Graft-Versus-Host Disease Drug Wins Orphan Status", "Merck's Antiviral Medicine Meets Endpoint in Phase III", "Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma", "AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted", "What's in Store for athenahealth (ATHN) in Q3 Earnings?", "Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study", "Shire Cancer Drug Onivyde Receives EU Marketing Approval", "41 Billion Reasons Why Gilead Sciences Might Need New Management", "J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales", "Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia", "PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal", "Shire (SHPG) Updates Vyvanse Label with New Efficacy Data", "Interesting EXEL Put And Call Options For January 2019", "The Medicines Co. Reports Positive Phase II Data on PCSK9si", "Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC", "Allergan (AGN) Gains Rights to RTGel from UroGen Pharma", "Allergan's Belkyra Gets Swedish Approval for Double Chin", "Natus Medical (BABY) Q3 Earnings: What's in the Cards?", "Enzo Biochem (ENZ) Looks Good: Stock Adds 11% in Session", "Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis", "Sunesis Submits Response to Questions on Leukemia Drug", "Tetraphase Begins Phase III Dosing of Antibiotic Candidate", "Intuitive Surgical (ISRG) Q3 Earnings: What's in Store?", "AMAG Issues Encouraging Updates on Makena & Feraheme", "Will These 5 Drug Stocks Be Big Winners This Earnings Season?", "Exelixis Goes for It", "Supernus (SUPN) Reports Encouraging Data from ADHD Study", "Momenta Pharmaceuticals (MNTA) Jumps: Stock Up 12.7%", "These 3 Little Biotechs Just Scored Big", "OncoGenex Cancer Drug Fails in Phase III Study, Stock Down", "Intuitive Surgical (ISRG) Q3 Earnings: What's in Store?", "FEX, FYX: Big ETF Inflows", "Fitbit Inc (FIT) Trapped in Middle of Several Extreme Opinions", "Exelixis Reaches Analyst Target Price", "Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year", "Goldman Sachs Group Inc (GS): Are We Entering the Next Recession?", "Total System Services, Inc (TSS) Lost Its Momentum", "Better Buy: Exelixis, Inc. vs. Roche", "Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide", "Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations", "Why Exelixis, Inc. Continued Its Downfall Today", "Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher", "Why Exelixis, Inc. Got Hammered Today", "Wednesday's ETF Movers: XOP, XBI", "Surging Earnings Estimates Signal Good News for Exelixis (EXEL)", "Exelixis, Inc. (EXEL) Crushed on CaboNivo Drug Trial Results", "3 Longs And 1 Short to Watch", "3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL)", "These 3 Stocks Have Doubled Their Investors' Money", "Forget Novavax, Buy These 4 Biotech Stocks Instead", "Will Exelixis (EXEL) Continue to Surge Higher?", "Wednesday's ETF Movers: XBI, XOP", "3 Stocks to Watch Wednesday: Monsanto Company (MON), Herbalife Ltd. (HLF) and Exelixis, Inc. (EXEL)", "First Week of May 2017 Options Trading For Exelixis (EXEL)", "Noteworthy Thursday Option Activity: EXPE, EXEL, JIVE", "Breaking Down Exelixis, Inc.'s Drug Launch", "Earnings Reaction History: Exelixis, Inc., 50.0% Follow-Through Indicator, 4.6% Sensitive", "A First Look at Exelixis, Inc.'s Rocket-Ship Drug", "Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?", "Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?", "Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More", "Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues", "Parker-Hannifin (PH) Q4 Earnings: Disappointment in Store?", "Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?", "Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?", "Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?", "What's in Store for Prothena (PRTA) This Earnings Season?", "Pfizer (PFE) Likely to Beat Earnings in Q2 Again", "Whta's in Store for Endocyte (ECYT) this Earnings Season?", "Geron (GERN) Q2 Earnings: What's in Store for the Stock?", "What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?", "Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?", "Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?", "Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?", "What's in Store for Prothena (PRTA) This Earnings Season?", "Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors", "Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?", "After Hours Most Active for Jul 1, 2016 : FBZ, TVIX, GE, BAC, T, JPM, XIV, PFE, WFC, EXEL, AAPL, MSFT", "After Hours Most Active for Jun 30, 2016 : LNT, ALB, EME, QQQ, SWX, MU, BAC, TE, YHOO, EXEL, IQNT, MSFT", "Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust", "Explosive Stocks Under $10", "5 Reasons to Hate Biotech Stocks", "4 Cancer Drug Developers You Need to Have on Your Radar This Year", "Exelixis, Inc. Setting New Standard of Care", "The Reason Why Exelixis Skyrocketed 20.5% in June", "Exelixis Up on Positive Kidney Cancer Data on Cabometyx", "Pre-Market Most Active for Jun 6, 2016 : TVIX, RDS/B, VBLT, AZN, CHK, ARIA, FCX, EXEL, RIO, BAC, XIV, MPEL", "Why Transocean, Exelixis, and CF Industries Jumped Today", "Roche Presents Encouraging Data on Actemra and Tecentriq", "Exelixis, Inc. Gets Some ASCO Love", "Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May", "These 2 Billionaires Are Dumping Exelixis' Stock. Should You?", "Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher", "After Hours Most Active for May 26, 2016 : CL, QQQ, EMC, BAC, AAPL, EXEL, T, FCX, TVIX, RAD, FOXA, MDLZ", "Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II", "Exelixis (EXEL) Worth a Look: Stock Up 8.1% in Session", "Exelixis (EXEL) Reports Wider-than-Expected Loss in Q1", "2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April", "Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More", "Exelixis (EXEL): What's Ahead for the Stock in Q1 Earnings?", "This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales", "Pre-Market Most Active for Apr 26, 2016 : SRPT, BP, SRC, MU, TVIX, AAPL, FCX, BBL, CPLP, BAC, RDS/B, EXEL", "Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!", "Mid-Afternoon Market Update: Crude Oil Down 2%; KKR Shares Slide Following Q1 Results", "Commit To Purchase Exelixis At $3.50, Earn 22.3% Annualized Using Options", "After Hours Most Active for Apr 12, 2016 : FDC, QQQ, PFE, HLT, VRX, LYG, WLL, CY, RRD, BRCD, EXEL, NVAX", "Ignore Exelixis, Inc.: Here Are 3 Better Stocks", "10 Biotech Stocks With Big Catalysts Coming This Quarter", "Better Buy: Exelixis, Inc. vs. Roche", "Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot", "Why Exelixis' Stock Dropped 10% on Tuesday", "Exelixis, Inc. Partnering Before Approval", "Exelixis Inc. Stock Was Throttled in February -- Here's Why", "3 Healthcare Stocks Short-Sellers Are Wrong About", "Exelixis (EXEL) Shows Strength: Stock Moves 5.2% Higher", "Exelixis Finally Snags a Licensing Partner for Cometriq", "Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb", "After Hours Most Active for Feb 25, 2016 : WTW, HPE, NRF, PFE, KHC, UN, BAC, MCHI, XIV, QQQ, EXEL, NVAX", "What's in Store for Exelixis (EXEL) this Earnings Season?", "Forget Gilead Sciences: These Stocks Doubled Last Year", "Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study", "Emotional Investing Deflates Exelixis, Inc. in January", "Why Exelixis, Inc. Rocketed Higher on Friday", "Exelixis's Cabozantinib Granted Priority Review in the U.S.", "Exelixis Loss Narrower than Expected, Cabozantinib in Focus", "Best Small-Cap Stocks of 2015", "1 George Soros Quote to Keep in Mind in 2016", "The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis", "5 Biotech Stocks That Doubled in 2015", "Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why", "Exelixis Reveals Data on Cabozantinib for Kidney Cancer", "The Top 5 Best Performing Biotech Stocks of 2015", "Bristol-Myers Squibb: A New Chapter, and the Beginning of Sustained Growth", "The Best Biotech Stocks in 2015", "Exelixis Submits Rolling NDA for Oncology Drug in the U.S.", "3 Biotech Stocks Under $5 That Could Explode Higher in 2016", "2 Healthcare Stocks That Dominated in 2015", "Why Exelixis, Inc. Is Trading Higher Today", "The Best Exelixis, Inc. Headlines in 2015", "Monday 12/14 Insider Buying Report: WLH, EXEL", "These 3 Companies Doubled in 2015", "Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod", "The FDA Approves Exelixis, Inc's New Cancer Drug", "Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf", "Did You Miss These Top Stories in Healthcare?", "Exelixis, Inc. Earnings: Riding the Meteor", "Are Investors Nuts To Be Short These Stocks?", "6 Stocks That Could Double In 2016", "These 3 Stocks Doubled Investors' Money This Year", "Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod", "The FDA Approves Exelixis, Inc's New Cancer Drug", "Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf", "Did You Miss These Top Stories in Healthcare?", "Exelixis, Inc. Earnings: Riding the Meteor", "Are Investors Nuts To Be Short These Stocks?", "6 Stocks That Could Double In 2016", "These 3 Stocks Doubled Investors' Money This Year", "The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem", "Earnings Reaction History: Exelixis, Inc., 40.0% Follow-Through Indicator, 3.5% Sensitive", "After-Hours Earnings Report for November 10, 2015 : DOX, KGC, HTHT, EXEL, INGN, NVGS, PNNT, OPWR, ARNA, HCKT, BOOT, EVDY", "What to Expect from Exelixis (EXEL) this Earnings Season?", "The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology", "5 Stocks That Doubled in 2015 -- And Keep Going Up", "3 Biotech Stocks to Buy in November", "Why Exelixis Shares Declined Today", "Agenus Q3 Loss Wider than Expected, Pipeline in Focus", "Use Options For a Chance To Buy EXEL at a 43% Discount", "Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer", "Interesting EXEL Put And Call Options For December 18th", "How Much Could Exelixis Really Be Worth?", "Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs", "Pre-Market Most Active for Oct 6, 2015 : PMCS, FCAU, AZN, FCX, ARMH, ILMN, BHP, TVIX, DD, AAPL, EXEL, PBR", "United Therapeutics Beats on Q3 Earnings, Revenues", "Exelixis' Cancer Drug Gets Breakthrough Therapy Status", "3 Small-Cap Biopharma Stocks I'd Never Short", "Exelixis Posts Wider-Than-Expected Loss, Focus on Pipeline", "Earnings Reaction History: Exelixis, Inc., 50.0% Follow-Through Indicator, 3.4% Sensitive", "After-Hours Earnings Report for August 11, 2015 : SYMC, CSC, SLW, FOSL, MYGN, PE, VIAV, EXEL, TAHO, EPAY, ZFGN, INGN", "Noteworthy ETF Outflows: XBI, ANAC, EXEL, XON", "Exelixis Up on Swiss Approval of Advanced Melanoma Drug", "Here's Why Exelixis' Stock Briefly Gained 10% Today", "Exelixis' Cancer Drug Gets Breakthrough Therapy Status", "3 Small-Cap Biopharma Stocks I'd Never Short", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog", "Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog", "This Explains Exelixis' METEOR-ic Rise in July", "Exelixis (EXEL) Shows Strength: Stock Adds 8.2% in Session - Tale of the Tape", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: July 26 - August 1", "Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape", "What to Expect from Exelixis (EXEL) This Earnings Season? (revised) - Analyst Blog", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog", "Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog", "This Explains Exelixis' METEOR-ic Rise in July", "Pre-Market Most Active for Jul 24, 2015 : EXEL, T, AMZN, BIIB, ITEK, FB, STM, QQQ, NOK, UN, ALU, CI", "The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases", "Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog", "After Hours Most Active for Jul 22, 2015 : QCOM, EXEL, QQQ, AA, WFM, RTI, RF, BAC, ACWI, EMC, EXC, FNBC", "Pre-Market Most Active for Jul 21, 2015 : NMR, PYPL, VZ, FB, AAPL, ABX, NOK, GPRO, PHG, PKX, QQQ, EXEL", "Potential Kidney Cancer Drugs Could Revolutionize Treatment", "Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog", "Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views", "5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary", "Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape", "Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape", "2 Stocks to Buy Now in Biotech", "These 3 Biotech Stocks Are Losing Money, But We'd Still Buy Them", "Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog", "Why Exelixis, Inc. Shares Slumped Today", "Small Cap Stocks to Watch in Biotech", "5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary", "Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape", "Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape", "2 Stocks to Buy Now in Biotech", "These 3 Biotech Stocks Are Losing Money, But We'd Still Buy Them", "Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog", "Financial Statement Analysis: 3 Metrics All Healthcare Investors Need to Know", "Cancer Stocks: 2 to Sell, 1 to Buy", "How 1 Sentence Caused Exelixis, Inc. to Soar in May", "Why Exelixis, Inc.'s Stock Briefly Spiked Today", "Pre-Market Most Active for Jun 1, 2015 : ONTY, ORAN, ALTR, VBLT, WFC, QQQ, BMY, AAPL, SFUN, STO, C, EXEL", "3 Stocks That Could Double Your Money", "Biotech Investment Opportunities for the Long Term", "1 Drug Will Make or Break These 3 Biotech Stocks", "Financial Statement Analysis: 3 Metrics All Healthcare Investors Need to Know", "Cancer Stocks: 2 to Sell, 1 to Buy", "Waiting for Exelixis, Inc.'s Meteor to Land", "Will Endocyte (ECYT) Disappoint This Earnings Season? - Analyst Blog", "Is Exelixis (EXEL) Likely to Report Narrower Loss in Q1? - Analyst Blog", "3 Biotech Stocks That May Disappear Before 2020", "Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog", "3 Soaring Biotech Stocks Under $10 -- Are They Buys?", "Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape", "The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners - Press Releases", "Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape", "Best Pure Play Investment in Cancer Drugs", "3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog", "2 Speculative Biotechs That Could Be Well Worth the Risk", "After Hours Most Active for Apr 14, 2015 : BAC, INTC, VALE, QQQ, MU, GE, BRCD, IGT, RF, CRC, STLD, EXEL", "Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog", "Looking Ahead at Exelixis, Inc.", "Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog", "Why Shares of Exelixis, Inc. Briefly Spiked Higher", "Pre-Market Most Active for Feb 19, 2015 : NOK, WMT, ING, PBR, MT, TVIX, ARIA, QQQ, AAPL, FB, EXEL, ALU", "Exelixis (EXEL) Catches Eye: Stock Adds 15.9% in Session - Tale of the Tape", "Why Exelixis, Inc. Shares Skyrocketed 57% in February", "XBI, FMI, EXEL, HALO: Large Inflows Detected at ETF", "Exelixis (EXEL) Shares March Higher, Can It Continue? - Tale of the Tape", "Why Exelixis, Inc. Shares Surged Higher By 30% in January", "Why Shares of Exelixis, Inc. Surged", "This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk", "The Surprising Thing Most of 2014's Top 10 Stocks Have in Common", "3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015", "Wednesday's ETF Movers: XBI, ILF", "3 Biotech Stocks That Could Double in 2015", "3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015", "The Most Disappointing Clinical Failures in 2014", "Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog", "Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog", "3 Healthcare Stocks to Watch in 2015", "Is Exelixis, Inc. Stock Doomed?", "Does This Drug Offer Exelixis Inc. Investors Hope for the Future?", "Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol", "Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip", "Exelixis' Cometriq Makes a Comeback", "Why Exelixis, Inc. Stock Pushed 11% Higher in October", "Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog", "Is Exelixis, Inc. Stock a Bad News Buy?", "3 Biotech Stocks Near 52-Week Lows Worth Buying", "Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog", "Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape", "Big News for These 5 Stocks From ESMO", "Why Exelixis, Inc. Stock Is Soaring Today", "Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape", "Why Exelixis Inc. Stock Crashed By 70% in 2014", "Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog", "Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape", "Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog", "Markets Mixed; Conn's Profit Misses Estimates", "U.S. Stock Futures Barely Higher Before Output, Spending Data", "US Futures Extend Gains After Strong August as Manufacturing Data Seen Higher", "Exelixis, Inc.'s Not So Excellent Prostate Cancer Trial Results", "Why Exelixis Inc. Stock Plunged", "Earnings Reaction History: Exelixis, Inc., 66.7% Follow-Through Indicator, 3.2% Sensitive", "Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape", "Exelixis Shares Slide On Trial Results; Norwegian Cruise Line Surges", "Pre-Market Most Active for Jul 15, 2014 : JPM, BAC, LO, VOD, EXEL, ALU, GPRO, FB, KNDI, ORAN, AAPL, GS", "Tuesday's ETF Movers: IYG, XBI", "Harmonic Drops On Weak Forecast; URS Shares Surge", "Pre-Market Most Active for Jul 14, 2014 : C, URS, AV, BAC, ABBV, MYL, PGNX, AAPL, GTAT, ALU, EXEL, QQQ", "Roche Presents Encouraging Data on Cobimetinib - Analyst Blog", "Sector Update: Health Care", "Sector Update: Health Care Stocks Holding Small Gains; Exelixis Rising on Cancer Drug Progress, Takeover Speculation", "Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape", "Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline", "Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast", "Pre-Market Most Active for Mar 26, 2014 : FCEL, INSM, BLDP, SIRI, FB, EXEL, LYG, VEEV, BAC, WFT, PBR, NOK", "Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises", "First Week of April 19th Options Trading For Exelixis (EXEL)", "Exelixis Q4 Loss In Line with Expectations - Analyst Blog", "Earnings Reaction History: Exelixis, Inc., 33.3% Follow-Through Indicator, 3.4% Sensitive", "Exelixis' Cometriq Approved in the EU - Analyst Blog", "Sector Update: Healthcare", "After Hours Most Active for Jan 22, 2014 : EBAY, QQQ, NFLX, BAC, EXEL, AVP, AA, FCX, COLE, MSFT, XOM, GILD", "Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher - Tale of the Tape", "Oversold ETFs Looking Attractive (IHE, CSD, PSCE)", "The 10 Stocks to Watch in 2014", "Pre-Market Most Active for Nov 4, 2013 : BBRY, ALU, FB, TOT, NOK, GSK, AKS, DRYS, JCP, QQQ, VOD, EXEL", "Pre-Market Most Active for Nov 1, 2013 : T, ABX, FB, CTL, AIG, PCAR, HOT, ALU, WDC, FSLR, EXEL, MDLZ", "Sector Update: Healthcare Stocks Lower; CBLI Slides 42% on Abandoned Development Plans", "After Hours Most Active for Oct 30, 2013 : FB, PBR/A, BEN, QQQ, EXPE, MCP, BAC, MNKD, CSCO, EXEL, AA, HCA", "After Hours Most Active for Oct 29, 2013 : ATVI, NOK, T, QQQ, RAD, RENN, FB, TTWO, YELP, TIBX, LNKD, EXEL", "Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years", "Healthcare Stocks Higher Near Close; Exelixis Climbs to New 52-Week High After Starting Liver-Cancer Drug Trial", "Sector Update: Healthcare", "Trade the Earnings: Exelixis, Inc.", "After Hours Most Active for Nov 1, 2013 : LUK, SMI, ERIC, QQQ, ARCP, ELN, BBRY, FB, DOLE, LOW, COLE, EXEL", "4 Biotech Stocks Ready to Explode", "After Hours Most Active for Sep 4, 2012 : LYB, HT, SHLD, QQQ, KGC, MTL, CVH, BAC, EXEL, MSFT, FB, FRAN", "After Hours Most Active for Aug 31, 2012 : QQQ, MO, ARR, MRK, BAC, CTL, EXEL, NIHD, ESV, INTC, SIRI, ARNA", "Pre-Market Most Active for Aug 9, 2012 : EXEL, RBN, NOK, BAC, CSCO, ALLY^A, SIRI, AHL, QQQ, WIN, SPH, MNST", "Time decay is key to Exelixis strategy", "Top Ten Undervalued Stocks With Large Cash Cushions", "Exelixis: Setting The Facts Straight", "Pipeline Advances at Exelixis - Analyst Blog", "4 Biotech Stocks Ready to Explode", "Momentum Ideas: Tuesday\u2019s High Volume Gainers", "Unusual option activity at halfway point", "4 Biotech Stocks That Could Pop", "Mid Day Update: Stocks Firmly Lower; Trade Deficit, Japan's Nuclear Situation Weigh", "US Indexes Broadly Lower; Alcoa Earnings, Trade Gap Weigh on Stocks", "5 Rallying Biotech Stocks Being Snapped Up By Insiders", "Bull takes a large dose of Exelixis", "Volatility seller returns to Exelixis", "How trade is callling a top in Exelixis"], "Elapsed Time": ["1 DAY AGO", "5 DAYS AGO", "JUN 8, 2020", "MAY 20, 2020", "MAY 15, 2020", "MAY 13, 2020", "MAY 6, 2020", "APR 30, 2020", "1 DAY AGO", "APR 24, 2020", "APR 22, 2020", "APR 21, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 20, 2020", "APR 29, 2020", "APR 20, 2020", "APR 18, 2020", "APR 16, 2020", "APR 10, 2020", "APR 8, 2020", "APR 2, 2020", "MAR 27, 2020", "APR 20, 2020", "MAR 22, 2020", "MAR 19, 2020", "MAR 15, 2020", "MAR 12, 2020", "MAR 6, 2020", "MAR 5, 2020", "MAR 2, 2020", "MAR 25, 2020", "FEB 26, 2020", "FEB 16, 2020", "FEB 12, 2020", "FEB 11, 2020", "FEB 7, 2020", "JAN 28, 2020", "JAN 23, 2020", "FEB 29, 2020", "JAN 19, 2020", "JAN 15, 2020", "JAN 14, 2020", "JAN 9, 2020", "JAN 6, 2020", "DEC 26, 2019", "JAN 22, 2020", "DEC 15, 2019", "DEC 13, 2019", "DEC 3, 2019", "NOV 26, 2019", "NOV 22, 2019", "NOV 18, 2019", "NOV 11, 2019", "DEC 23, 2019", "OCT 31, 2019", "OCT 31, 2019", "OCT 14, 2019", "OCT 11, 2019", "OCT 4, 2019", "SEP 17, 2019", "SEP 5, 2019", "NOV 11, 2019", "AUG 30, 2019", "AUG 25, 2019", "AUG 21, 2019", "AUG 16, 2019", "AUG 5, 2019", "AUG 1, 2019", "JUL 31, 2019", "SEP 4, 2019", "JUL 24, 2019", "JUL 8, 2019", "JUN 30, 2019", "JUN 29, 2019", "JUN 28, 2019", "JUN 24, 2019", "JUN 21, 2019", "JUL 26, 2019", "JUN 6, 2019", "JUN 3, 2019", "MAY 21, 2019", "MAY 14, 2019", "MAY 7, 2019", "MAY 2, 2019", "APR 29, 2019", "JUN 17, 2019", "JUN 6, 2019", "APR 23, 2019", "APR 20, 2019", "APR 19, 2019", "APR 19, 2019", "APR 18, 2019", "APR 16, 2019", "APR 25, 2019", "APR 10, 2019", "APR 8, 2019", "APR 5, 2019", "APR 3, 2019", "MAR 14, 2019", "MAR 14, 2019", "MAR 12, 2019", "APR 11, 2019", "MAR 5, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 17, 2019", "FEB 15, 2019", "FEB 14, 2019", "FEB 13, 2019", "MAR 8, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 13, 2019", "FEB 7, 2019", "FEB 5, 2019", "JAN 24, 2019", "JAN 18, 2019", "JAN 17, 2019", "JAN 15, 2019", "JAN 14, 2019", "FEB 8, 2019", "FEB 7, 2019", "JAN 8, 2019", "JAN 8, 2019", "JAN 4, 2019", "DEC 28, 2018", "DEC 27, 2018", "DEC 24, 2018", "JAN 11, 2019", "DEC 15, 2018", "DEC 14, 2018", "DEC 13, 2018", "DEC 12, 2018", "DEC 9, 2018", "DEC 4, 2018", "DEC 1, 2018", "DEC 17, 2018", "NOV 26, 2018", "NOV 26, 2018", "NOV 23, 2018", "NOV 15, 2018", "NOV 15, 2018", "NOV 8, 2018", "NOV 5, 2018", "NOV 30, 2018", "NOV 26, 2018", "NOV 26, 2018", "NOV 23, 2018", "NOV 15, 2018", "OCT 30, 2018", "OCT 19, 2018", "NOV 2, 2018", "OCT 8, 2018", "OCT 3, 2018", "OCT 3, 2018", "SEP 26, 2018", "SEP 24, 2018", "SEP 23, 2018", "SEP 20, 2018", "OCT 17, 2018", "OCT 8, 2018", "OCT 3, 2018", "SEP 10, 2018", "SEP 5, 2018", "SEP 1, 2018", "AUG 31, 2018", "SEP 19, 2018", "AUG 20, 2018", "AUG 20, 2018", "AUG 20, 2018", "AUG 16, 2018", "AUG 14, 2018", "AUG 6, 2018", "AUG 2, 2018", "AUG 30, 2018", "JUL 27, 2018", "JUL 25, 2018", "JUL 18, 2018", "JUL 10, 2018", "JUN 29, 2018", "JUN 28, 2018", "JUN 27, 2018", "AUG 1, 2018", "MAY 31, 2018", "MAY 23, 2018", "MAY 23, 2018", "MAY 19, 2018", "MAY 17, 2018", "MAY 14, 2018", "MAY 11, 2018", "JUN 26, 2018", "MAY 31, 2018", "MAY 23, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 8, 2018", "MAY 4, 2018", "MAY 4, 2018", "MAY 3, 2018", "MAY 10, 2018", "MAY 9, 2018", "MAY 9, 2018", "APR 12, 2018", "APR 11, 2018", "APR 10, 2018", "APR 6, 2018", "APR 6, 2018", "MAY 3, 2018", "APR 30, 2018", "APR 19, 2018", "APR 12, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 13, 2018", "APR 4, 2018", "APR 4, 2018", "MAR 28, 2018", "MAR 26, 2018", "MAR 23, 2018", "MAR 14, 2018", "FEB 27, 2018", "MAR 1, 2018", "FEB 28, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 27, 2018", "MAR 1, 2018", "FEB 27, 2018", "FEB 26, 2018", "FEB 21, 2018", "FEB 21, 2018", "FEB 21, 2018", "FEB 20, 2018", "FEB 22, 2018", "FEB 20, 2018", "FEB 20, 2018", "FEB 20, 2018", "FEB 20, 2018", "FEB 19, 2018", "FEB 19, 2018", "FEB 19, 2018", "FEB 20, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 16, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 13, 2018", "FEB 13, 2018", "FEB 15, 2018", "FEB 12, 2018", "FEB 12, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 12, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 7, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 8, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 2, 2018", "FEB 6, 2018", "FEB 2, 2018", "FEB 2, 2018", "FEB 2, 2018", "FEB 1, 2018", "FEB 1, 2018", "JAN 31, 2018", "JAN 31, 2018", "FEB 2, 2018", "JAN 30, 2018", "JAN 30, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 25, 2018", "JAN 31, 2018", "JAN 24, 2018", "JAN 24, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 25, 2018", "JAN 25, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 22, 2018", "JAN 19, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 23, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 16, 2018", "JAN 15, 2018", "JAN 15, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 16, 2018", "JAN 15, 2018", "JAN 15, 2018", "JAN 15, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 11, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 11, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 5, 2018", "JAN 9, 2018", "JAN 4, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 3, 2018", "DEC 28, 2017", "DEC 28, 2017", "DEC 26, 2017", "JAN 4, 2018", "DEC 22, 2017", "DEC 21, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 12, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 21, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 20, 2017", "DEC 12, 2017", "DEC 22, 2017", "DEC 22, 2017", "DEC 21, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 16, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 2, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 2, 2017", "NOV 1, 2017", "NOV 1, 2017", "OCT 31, 2017", "NOV 2, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 24, 2017", "OCT 21, 2017", "OCT 18, 2017", "OCT 17, 2017", "OCT 30, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 13, 2017", "OCT 5, 2017", "OCT 16, 2017", "OCT 2, 2017", "SEP 30, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 26, 2017", "SEP 25, 2017", "SEP 24, 2017", "OCT 4, 2017", "SEP 22, 2017", "SEP 20, 2017", "SEP 15, 2017", "SEP 15, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 10, 2017", "SEP 22, 2017", "SEP 8, 2017", "SEP 6, 2017", "SEP 1, 2017", "AUG 30, 2017", "AUG 27, 2017", "AUG 24, 2017", "AUG 22, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 6, 2017", "SEP 1, 2017", "AUG 9, 2017", "AUG 4, 2017", "AUG 4, 2017", "AUG 21, 2017", "AUG 17, 2017", "AUG 15, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 2, 2017", "AUG 1, 2017", "AUG 4, 2017", "JUL 31, 2017", "JUL 31, 2017", "JUL 28, 2017", "JUL 28, 2017", "JUL 28, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 31, 2017", "JUL 27, 2017", "JUL 26, 2017", "JUL 24, 2017", "JUL 21, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 26, 2017", "JUL 24, 2017", "JUL 21, 2017", "JUL 20, 2017", "JUL 13, 2017", "JUL 19, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 12, 2017", "JUL 11, 2017", "JUL 11, 2017", "JUL 7, 2017", "JUL 7, 2017", "JUL 13, 2017", "JUL 5, 2017", "JUL 5, 2017", "JUL 5, 2017", "JUL 3, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUL 6, 2017", "JUN 25, 2017", "JUN 24, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 27, 2017", "JUN 21, 2017", "JUN 20, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 13, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 20, 2017", "JUN 19, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "JUN 2, 2017", "MAY 2, 2017", "MAY 1, 2017", "MAY 1, 2017", "APR 29, 2017", "APR 28, 2017", "APR 28, 2017", "APR 27, 2017", "MAY 2, 2017", "APR 25, 2017", "APR 24, 2017", "APR 23, 2017", "APR 20, 2017", "APR 18, 2017", "APR 18, 2017", "APR 12, 2017", "APR 27, 2017", "APR 25, 2017", "APR 24, 2017", "APR 23, 2017", "APR 20, 2017", "APR 18, 2017", "APR 18, 2017", "APR 12, 2017", "APR 27, 2017", "APR 25, 2017", "APR 24, 2017", "APR 23, 2017", "APR 20, 2017", "APR 18, 2017", "APR 18, 2017", "MAR 12, 2017", "APR 11, 2017", "APR 9, 2017", "APR 4, 2017", "MAR 20, 2017", "MAR 15, 2017", "MAR 14, 2017", "MAR 13, 2017", "MAR 12, 2017", "APR 11, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 6, 2017", "MAR 2, 2017", "MAR 1, 2017", "FEB 28, 2017", "FEB 28, 2017", "MAR 7, 2017", "FEB 24, 2017", "FEB 24, 2017", "FEB 23, 2017", "FEB 23, 2017", "FEB 23, 2017", "FEB 23, 2017", "FEB 23, 2017", "FEB 24, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 21, 2017", "FEB 23, 2017", "FEB 20, 2017", "FEB 17, 2017", "FEB 17, 2017", "FEB 17, 2017", "FEB 14, 2017", "FEB 13, 2017", "FEB 9, 2017", "FEB 13, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 13, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 2, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 7, 2017", "FEB 7, 2017", "FEB 2, 2017", "FEB 8, 2017", "JAN 29, 2017", "JAN 23, 2017", "JAN 11, 2017", "DEC 29, 2016", "DEC 27, 2016", "DEC 23, 2016", "DEC 23, 2016", "JAN 5, 2017", "DEC 22, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 19, 2016", "DEC 18, 2016", "DEC 16, 2016", "DEC 14, 2016", "DEC 22, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 7, 2016", "NOV 22, 2016", "DEC 1, 2016", "DEC 1, 2016", "NOV 18, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 18, 2016", "NOV 16, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 11, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 12, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 9, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 5, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 3, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 28, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 28, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 25, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 20, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 21, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 17, 2016", "OCT 19, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 12, 2016", "OCT 11, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 7, 2016", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "SEP 30, 2016", "SEP 30, 2016", "OCT 8, 2016", "SEP 29, 2016", "SEP 29, 2016", "SEP 29, 2016", "SEP 29, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 26, 2016", "SEP 30, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 17, 2016", "SEP 16, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 21, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 4, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 28, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 10, 2016", "JUL 27, 2016", "JUL 1, 2016", "JUN 30, 2016", "JUN 29, 2016", "JUN 28, 2016", "JUN 23, 2016", "JUN 15, 2016", "JUN 8, 2016", "JUL 8, 2016", "JUN 7, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 3, 2016", "MAY 31, 2016", "JUN 7, 2016", "MAY 26, 2016", "MAY 24, 2016", "MAY 16, 2016", "MAY 5, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 2, 2016", "MAY 27, 2016", "APR 26, 2016", "APR 26, 2016", "APR 25, 2016", "APR 14, 2016", "APR 12, 2016", "APR 7, 2016", "MAR 31, 2016", "APR 27, 2016", "MAR 15, 2016", "MAR 9, 2016", "MAR 7, 2016", "MAR 6, 2016", "MAR 5, 2016", "MAR 2, 2016", "MAR 1, 2016", "MAR 15, 2016", "FEB 25, 2016", "FEB 25, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 2, 2016", "JAN 29, 2016", "JAN 29, 2016", "MAR 1, 2016", "JAN 12, 2016", "JAN 10, 2016", "JAN 8, 2016", "JAN 7, 2016", "JAN 6, 2016", "JAN 5, 2016", "JAN 2, 2016", "JAN 15, 2016", "DEC 28, 2015", "DEC 28, 2015", "DEC 27, 2015", "DEC 27, 2015", "DEC 23, 2015", "DEC 22, 2015", "DEC 14, 2015", "DEC 31, 2015", "NOV 26, 2015", "NOV 23, 2015", "NOV 23, 2015", "NOV 16, 2015", "NOV 15, 2015", "NOV 14, 2015", "NOV 14, 2015", "DEC 10, 2015", "NOV 26, 2015", "NOV 23, 2015", "NOV 23, 2015", "NOV 16, 2015", "NOV 15, 2015", "NOV 14, 2015", "NOV 14, 2015", "DEC 10, 2015", "NOV 11, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 9, 2015", "NOV 5, 2015", "NOV 4, 2015", "NOV 1, 2015", "NOV 11, 2015", "OCT 28, 2015", "OCT 27, 2015", "OCT 23, 2015", "OCT 21, 2015", "OCT 9, 2015", "OCT 8, 2015", "OCT 6, 2015", "OCT 28, 2015", "AUG 25, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 10, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 25, 2015", "AUG 12, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 27, 2015", "AUG 5, 2015", "AUG 5, 2015", "AUG 4, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 27, 2015", "AUG 5, 2015", "JUL 24, 2015", "JUL 23, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 21, 2015", "JUL 20, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 21, 2015", "JUL 2, 2015", "JUL 1, 2015", "JUN 30, 2015", "JUN 25, 2015", "JUN 25, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 21, 2015", "JUL 2, 2015", "JUN 12, 2015", "JUN 10, 2015", "JUN 2, 2015", "JUN 1, 2015", "JUN 1, 2015", "MAY 30, 2015", "MAY 30, 2015", "JUN 13, 2015", "JUN 12, 2015", "MAY 1, 2015", "MAY 1, 2015", "APR 29, 2015", "APR 29, 2015", "APR 15, 2015", "APR 27, 2015", "APR 22, 2015", "APR 20, 2015", "APR 20, 2015", "APR 20, 2015", "APR 19, 2015", "APR 17, 2015", "APR 14, 2015", "APR 14, 2015", "APR 10, 2015", "FEB 25, 2015", "FEB 23, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 11, 2015", "MAR 3, 2015", "FEB 27, 2015", "FEB 27, 2015", "FEB 5, 2015", "JAN 28, 2015", "JAN 26, 2015", "JAN 11, 2015", "JAN 7, 2015", "FEB 11, 2015", "DEC 29, 2014", "DEC 23, 2014", "DEC 21, 2014", "DEC 17, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 2, 2014", "JAN 2, 2015", "DEC 1, 2014", "DEC 1, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 3, 2014", "OCT 13, 2014", "OCT 8, 2014", "DEC 2, 2014", "OCT 3, 2014", "SEP 30, 2014", "SEP 29, 2014", "SEP 18, 2014", "SEP 13, 2014", "SEP 3, 2014", "SEP 3, 2014", "OCT 3, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "SEP 2, 2014", "JUL 31, 2014", "JUL 25, 2014", "SEP 2, 2014", "JUL 15, 2014", "JUL 15, 2014", "JUL 14, 2014", "JUL 14, 2014", "JUL 14, 2014", "JUL 14, 2014", "JUL 14, 2014", "JUL 15, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 26, 2014", "FEB 26, 2014", "FEB 21, 2014", "FEB 20, 2014", "MAR 27, 2014", "JAN 23, 2014", "JAN 22, 2014", "JAN 7, 2014", "DEC 17, 2013", "NOV 19, 2013", "NOV 4, 2013", "NOV 1, 2013", "JAN 23, 2014", "OCT 30, 2013", "OCT 29, 2013", "OCT 9, 2013", "SEP 10, 2013", "SEP 10, 2013", "AUG 6, 2013", "NOV 1, 2013", "SEP 6, 2012", "SEP 4, 2012", "AUG 31, 2012", "AUG 9, 2012", "NOV 22, 2011", "NOV 21, 2011", "NOV 7, 2011", "JAN 18, 2013", "SEP 6, 2012", "JUN 8, 2011", "JUN 6, 2011", "MAY 18, 2011", "APR 12, 2011", "APR 12, 2011", "FEB 24, 2011", "SEP 22, 2011", "OCT 4, 2010", "DEC 15, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/3-biotech-stocks-id-buy-right-now-2020-06-27", "https://www.nasdaq.com/articles/analysts-predict-10-gains-ahead-for-the-holdings-of-mdy-2020-06-22", "https://www.nasdaq.com/articles/how-biotech-companies-are-valued-2020-06-08", "https://www.nasdaq.com/articles/we-did-the-math-iwr-can-go-to-%2456-2020-05-20", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-for-july-17th-2020-05-15", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-exelixis-2020-05-13", "https://www.nasdaq.com/articles/exelixis-inc-exel-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/uso-idna%3A-big-etf-inflows-2020-04-30", "https://www.nasdaq.com/articles/3-biotech-stocks-id-buy-right-now-2020-06-27", "https://www.nasdaq.com/articles/better-buy%3A-anaptysbio-vs.-exelixis-2020-04-24", "https://www.nasdaq.com/articles/exelixis-reaches-analyst-target-price-2020-04-22", "https://www.nasdaq.com/articles/cycc-in-stopcovid-exel-hits-new-high-nvs-trialing-malaria-drug-for-covid-19-2020-04-21", "https://www.nasdaq.com/articles/bristol-myers-squibbs-cancer-drug-opdivo-successful-in-2-clinical-trials-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dupont-occidental-petroleum-safe-t-group-2020-04-20", "https://www.nasdaq.com/articles/why-exelixis-stock-is-skyrocketing-today-2020-04-20", "https://www.nasdaq.com/articles/first-trust-nyse-arca-biotechnology-index-fund-experiences-big-inflow-2020-04-29", "https://www.nasdaq.com/articles/have-%245000-then-buy-these-top-stocks-on-any-coronavirus-weakness-2020-04-20", "https://www.nasdaq.com/articles/2-biotechs-battling-against-kidney-cancer-2020-04-18", "https://www.nasdaq.com/articles/is-exelixis-a-buy-2020-04-16", "https://www.nasdaq.com/articles/have-an-extra-%241000-buy-these-2-biotech-stocks-2020-04-10", "https://www.nasdaq.com/articles/2-cancer-stocks-that-could-make-you-filthy-rich-2020-04-08", "https://www.nasdaq.com/articles/3-top-stocks-that-will-make-you-richer-in-q2-and-beyond-2020-04-02", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-for-november-20th-2020-03-27", "https://www.nasdaq.com/articles/bristol-myers-says-opdivo-performs-well-in-kidney-lung-cancer-trials-2020-04-20", "https://www.nasdaq.com/articles/coronavirus-crisis%3A-3-biotech-stocks-to-buy-right-now-2020-03-22", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2020-03-19", "https://www.nasdaq.com/articles/why-anaptysbio-bluebird-bio-and-exelixis-shares-rebounded-last-friday-2020-03-15", "https://www.nasdaq.com/articles/heres-why-nuvasive-exelixis-and-natus-medical-fell-today-2020-03-12", "https://www.nasdaq.com/articles/6-quality-biotech-stocks-on-sale-now-2020-03-06", "https://www.nasdaq.com/articles/3-biotech-stocks-that-are-coronavirus-safe-havens-2020-03-05", "https://www.nasdaq.com/articles/exel-crosses-above-key-moving-average-level-2020-03-02", "https://www.nasdaq.com/articles/have-%242500-then-buy-these-4-cash-rich-stocks-now-2020-03-25", "https://www.nasdaq.com/articles/exelixis-inc-exel-q4-2019-earnings-call-transcript-2020-02-26", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/3-mid-cap-growth-stocks-to-buy-2020-02-12", "https://www.nasdaq.com/articles/exelixis-reports-positive-results-in-metastatic-castration-resistant-prostate-cancer-study", "https://www.nasdaq.com/articles/3-stocks-ill-never-sell-2020-02-07", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2020-01-28", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-for-june-19th-2020-01-23", "https://www.nasdaq.com/articles/investors-endure-wild-ride-in-this-biotech-taking-on-covid-19-2020-02-29", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/5-mid-cap-stocks-youll-want-to-own-in-2020-2020-01-15", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-exel-2020-01-14", "https://www.nasdaq.com/articles/5-value-stocks-that-will-make-you-richer-in-2020-2020-01-09", "https://www.nasdaq.com/articles/10-top-stocks-that-will-make-you-richer-in-2020-2020-01-06", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-for-august-2020-2019-12-26", "https://www.nasdaq.com/articles/can-investors-excel-in-2020-with-exelixis-2020-01-22", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-david-dreman-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-13-2019%3A-srpt-blrx-exel-jnj-pfe-abt-mrk-amgn-2019-12-13", "https://www.nasdaq.com/articles/3-top-growth-stocks-to-buy-in-december-2019-12-03", "https://www.nasdaq.com/articles/why-did-farallon-capital-get-out-of-these-3-biotech-stocks-2019-11-26", "https://www.nasdaq.com/articles/3-stocks-peter-lynch-would-love-2019-11-22", "https://www.nasdaq.com/articles/exelixis-stock-regains-its-mojo-2019-11-18", "https://www.nasdaq.com/articles/why-exelixis-stock-broke-down-in-october-2019-11-11", "https://www.nasdaq.com/articles/2-incredibly-cheap-biotech-stocks-2019-12-23", "https://www.nasdaq.com/articles/heres-why-exelexis-sank-today-2019-10-31", "https://www.nasdaq.com/articles/exelixis-inc-exel-q3-2019-earnings-call-transcript-2019-10-31", "https://www.nasdaq.com/articles/7-under-the-radar-growth-stocks-that-could-benefit-new-investors-2019-10-14", "https://www.nasdaq.com/articles/will-the-pace-of-ma-pick-up-following-the-biotech-sectors-pounding-2019-10-11", "https://www.nasdaq.com/articles/3-mid-cap-biotech-stocks-to-consider-buying-now-2019-10-04", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-for-january-2022-2019-09-17", "https://www.nasdaq.com/articles/implied-useq-analyst-target-price%3A-%2431-2019-09-05", "https://www.nasdaq.com/articles/20-stocks-that-could-double-your-money-in-2020-2019-11-11", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-exel-iipr-team-2019-08-30", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2019-08-25", "https://www.nasdaq.com/articles/10-small-cap-up-and-coming-stocks-to-keep-on-your-radar-2019-08-21", "https://www.nasdaq.com/articles/first-week-of-exel-september-20th-options-trading-2019-08-16", "https://www.nasdaq.com/articles/exelixis-hits-blockbuster-status-2019-08-05", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-exel-2019-08-01", "https://www.nasdaq.com/articles/exelixis-inc-exel-q2-2019-earnings-call-transcript-2019-08-01", "https://www.nasdaq.com/articles/wednesdays-etf-movers%3A-oih-fbt-2019-09-04", "https://www.nasdaq.com/articles/10-small-cap-up-and-coming-stocks-to-keep-on-your-radar-2019-07-24", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-exel-2019-07-08", "https://www.nasdaq.com/articles/is-exelixis-a-buy-2019-06-30", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-2019-06-29", "https://www.nasdaq.com/articles/first-week-of-february-2020-options-trading-for-exelixis-exel-2019-06-28", "https://www.nasdaq.com/articles/read-this-before-you-buy-any-new-cancer-drug-stocks-2019-06-24", "https://www.nasdaq.com/articles/oh-by-the-way-this-clinical-trial-didnt-work-2019-06-21", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2019-07-26", "https://www.nasdaq.com/articles/top-5-stocks-fight-against-cancer-2019-06-06", "https://www.nasdaq.com/articles/analysts-predict-17-upside-pwc-2019-06-03", "https://www.nasdaq.com/articles/exel-crosses-above-key-moving-average-level-2019-05-21", "https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2019-05-14", "https://www.nasdaq.com/articles/where-will-gilead-sciences-spend-its-cash-2019-05-07", "https://www.nasdaq.com/articles/exelixis-inc-exel-q1-2019-earnings-call-transcript-2019-05-02", "https://www.nasdaq.com/articles/2-incredibly-cheap-value-stocks-buy-now-2019-04-29", "https://www.nasdaq.com/articles/exelixis-exel-shares-cross-above-200-dma-2019-06-17", "https://www.nasdaq.com/articles/top-5-stocks-fight-against-cancer-2019-06-06", "https://www.nasdaq.com/articles/kidney-cancer-market-good-patients-hard-investors-2019-04-23", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-buy-april-2019-04-20", "https://www.nasdaq.com/articles/5-top-pharmaceutical-stocks-buy-2019-2019-04-19", "https://www.nasdaq.com/articles/5-top-biotech-stocks-buy-2019-2019-04-19", "https://www.nasdaq.com/articles/exelixis-now-oversold-exel-2019-04-18", "https://www.nasdaq.com/articles/proqr-initiates-dosing-in-phase-ii-iii-eye-disorder-study-2019-04-16-0", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-25-2019%3A-wstbmyexelalks-2019-04-25", "https://www.nasdaq.com/articles/first-week-exel-november-15th-options-trading-2019-04-10", "https://www.nasdaq.com/articles/8-stocks-to-buy-that-are-growing-faster-than-amazon-2019-04-08", "https://www.nasdaq.com/articles/exelixis-exel-rallies-22.4-ytd%3A-what-to-expect-ahead-2019-04-05-0", "https://www.nasdaq.com/articles/after-hours-most-active-apr-3-2019-cmcsa-bbd-parr-bac-cnhi-ebay-msft-ual-aes-syf-achc-exel", "https://www.nasdaq.com/articles/why-is-exelixis-exel-up-12.1-since-last-earnings-report-2019-03-14", "https://www.nasdaq.com/articles/exelixis-exel-gains-as-market-dips%3A-what-you-should-know-2019-03-14", "https://www.nasdaq.com/articles/pfizers-pfe-kidney-cancer-drug-combo-gets-emas-validation-2019-03-12", "https://www.nasdaq.com/articles/risk-tolerant-investors-turn-your-eyes-exelixis-stock-2019-04-11", "https://www.nasdaq.com/articles/3-best-biotech-bargain-stocks-market-right-now-2019-03-05", "https://www.nasdaq.com/articles/pfizers-forgotten-cancer-pill-about-become-its-next-blockbuster-2019-02-19", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-pbe-2019-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-david-dreman-2172019-2019-02-17", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-15th-2019-02-15", "https://www.nasdaq.com/articles/implied-volatility-surging-for-exelixis-exel-stock-options-2019-02-14", "https://www.nasdaq.com/articles/health-care-sector-update-02132019-baby-teva-exel-jnj-pfe-abt-mrk-amgn-2019-02-13", "https://www.nasdaq.com/articles/exelixis-exel-dips-more-than-broader-markets%3A-what-you-should-know-2019-03-08", "https://www.nasdaq.com/articles/exelixis-grabs-90-first-place-2019-02-13", "https://www.nasdaq.com/articles/health-care-sector-update-02132019-tevaexelbaby-2019-02-13", "https://www.nasdaq.com/articles/exelixis-exel-earnings-revenues-beat-estimates-in-q4-2019-02-13", "https://www.nasdaq.com/articles/exelixis-inc-exel-q4-2018-earnings-conference-call-transcript-2019-02-12", "https://www.nasdaq.com/articles/exelixis-exel-tops-q4-earnings-and-revenue-estimates-2019-02-12", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-12-2019-oxy-atvi-acgl-udr-akam-twlo-trip-bfam-hubs", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-750-follow-through-indicator-87-sensitive-2019-02", "https://www.nasdaq.com/articles/health-care-sector-update-02132019-crltevaexelbaby-2019-02-13", "https://www.nasdaq.com/articles/8-stocks-to-buy-that-are-growing-faster-than-amazon-2019-02-07", "https://www.nasdaq.com/articles/exelixis-exel-earnings-expected-to-grow%3A-should-you-buy-2019-02-05", "https://www.nasdaq.com/articles/how-pieces-add-oneo-headed-77-2019-01-24", "https://www.nasdaq.com/articles/exelixis-exel-stock-sinks-as-market-gains%3A-what-you-should-know-2019-01-18", "https://www.nasdaq.com/articles/amgens-postmenopausal-osteoporosis-drug-gets-fda-panel-nod-2019-01-17", "https://www.nasdaq.com/articles/exelixis-cabometyx-tablets-receive-fda-nod-for-liver-cancer-2019-01-15", "https://www.nasdaq.com/articles/5-reasons-why-investors-should-buy-exelixis-exel-in-2019-2019-01-14", "https://www.nasdaq.com/articles/notable-friday-option-activity-cyh-exel-ubnt-2019-02-08", "https://www.nasdaq.com/articles/8-stocks-to-buy-that-are-growing-faster-than-amazon-2019-02-07", "https://www.nasdaq.com/articles/health-care-sector-update-01082019-orgoexelaxsmakrx-2019-01-08", "https://www.nasdaq.com/articles/health-care-sector-update-01082019-exelaxsmakrx-2019-01-08", "https://www.nasdaq.com/articles/after-hours-most-active-jan-4-2019-qqq-ge-trco-frc-info-oas-eqt-yelp-gogo-exel-fb-ssnc", "https://www.nasdaq.com/articles/exel-makes-bullish-cross-above-critical-moving-average-2018-12-28", "https://www.nasdaq.com/articles/alexions-alxn-soliris-drives-growth-amid-pricing-pressure-2018-12-27", "https://www.nasdaq.com/articles/math-shows-oneo-can-go-82-2018-12-24", "https://www.nasdaq.com/articles/exelixis-exel-dips-more-than-broader-markets%3A-what-you-should-know-2019-01-11", "https://www.nasdaq.com/articles/3-biotechs-gilead-sciences-could-buy-march-2018-12-15", "https://www.nasdaq.com/articles/5-biotech-stocks-set-bounce-back-19-after-rough-ride-2018-12-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-conatus-pharmaceuticals-biogen-ionis", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilead-to-get-new-ceo-biogen-in-licenses-candidate-2018-12-12", "https://www.nasdaq.com/articles/heres-why-exelixis-stock-jumped-464-november-2018-12-09", "https://www.nasdaq.com/articles/why-exelixis-exel-could-be-positioned-for-a-surge-2018-12-04", "https://www.nasdaq.com/articles/why-is-exelixis-exel-up-35.9-since-last-earnings-report-2018-12-01", "https://www.nasdaq.com/articles/5-excellent-garp-picks-with-cheap-peg-ratio-2018-12-17", "https://www.nasdaq.com/articles/3-top-growth-stocks-buy-right-now-2018-11-26", "https://www.nasdaq.com/articles/spark-therapeutics-luxturna-gets-eu-approval-for-vision-loss-2018-11-26", "https://www.nasdaq.com/articles/sarepta-stock-more-than-doubles-this-year-so-far%3A-heres-why-2018-11-23", "https://www.nasdaq.com/articles/exelixis-ipsen-get-eu-nod-for-label-expansion-of-cabometyx-2018-11-15", "https://www.nasdaq.com/articles/health-care-sector-update-11152018-qure-exel-aveo-jnj-pfe-mrk-abt-amgn-2018-11-15", "https://www.nasdaq.com/articles/can-exelixis-exel-run-higher-on-rising-earnings-estimates-2018-11-08", "https://www.nasdaq.com/articles/exelixis-grabs-its-share-kidney-cancer-treatment-market-2018-11-05", "https://www.nasdaq.com/articles/exel-makes-bullish-cross-above-critical-moving-average-2018-11-30", "https://www.nasdaq.com/articles/3-top-growth-stocks-buy-right-now-2018-11-26", "https://www.nasdaq.com/articles/spark-therapeutics-luxturna-gets-eu-approval-for-vision-loss-2018-11-26", "https://www.nasdaq.com/articles/sarepta-stock-more-than-doubles-this-year-so-far%3A-heres-why-2018-11-23", "https://www.nasdaq.com/articles/exelixis-ipsen-get-eu-nod-for-label-expansion-of-cabometyx-2018-11-15", "https://www.nasdaq.com/articles/exelixis-exel-to-report-q3-earnings%3A-whats-in-store-2018-10-30", "https://www.nasdaq.com/articles/why-mercks-latest-success-means-trouble-exelixis-inc-2018-10-19", "https://www.nasdaq.com/articles/exelixis-inc-exel-q3-2018-earnings-conference-call-transcript-2018-11-02", "https://www.nasdaq.com/articles/why-the-earnings-surprise-streak-could-continue-for-exelixis-exel-2018-10-08", "https://www.nasdaq.com/articles/3-top-mid-cap-stocks-buy-october-2018-10-03", "https://www.nasdaq.com/articles/8-stocks-buy-are-growing-faster-amazon-2018-10-03", "https://www.nasdaq.com/articles/first-week-exel-may-2019-options-trading-2018-09-26", "https://www.nasdaq.com/articles/exelixis-ipsen-receive-positive-chmp-opinion-for-cabometyx-2018-09-24", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-09-23", "https://www.nasdaq.com/articles/exelixis-partner-ipsen-gets-approval-for-cabometyx-in-canada-2018-09-20", "https://www.nasdaq.com/articles/5-beaten-down-biotech-stocks-pick-wreckage-2018-10-17", "https://www.nasdaq.com/articles/why-the-earnings-surprise-streak-could-continue-for-exelixis-exel-2018-10-08", "https://www.nasdaq.com/articles/3-top-mid-cap-stocks-buy-october-2018-10-03", "https://www.nasdaq.com/articles/exelixis-cabometyx-recommended-by-nccn-for-all-types-of-rcc-2018-09-10", "https://www.nasdaq.com/articles/3-monster-biotech-stocks-making-2018-09-05", "https://www.nasdaq.com/articles/exelixis-exel-down-14.1-since-last-earnings-report%3A-can-it-rebound-2018-09-01", "https://www.nasdaq.com/articles/3-stocks-could-put-apples-returns-shame-2018-08-31", "https://www.nasdaq.com/articles/7-biotech-stocks-buy-now-2018-09-19", "https://www.nasdaq.com/articles/relative-strength-alert-exelixis-2018-08-20", "https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20", "https://www.nasdaq.com/articles/monday-sector-laggards-biotechnology-drugs-2018-08-20", "https://www.nasdaq.com/articles/better-speculative-biotech-stock-amarin-corporation-vs-geron-corporation-2018-08-16", "https://www.nasdaq.com/articles/13-cheapest-healthcare-stocks-2018-08-14", "https://www.nasdaq.com/articles/exelixis-gets-patients-eventually-2018-08-06", "https://www.nasdaq.com/articles/heres-why-exelixis-stock-jumped-higher-today-2018-08-02", "https://www.nasdaq.com/articles/beaten-down-exelixis-inc-buy-now-2018-08-30", "https://www.nasdaq.com/articles/is-exelixis-exel-poised-for-a-beat-again-in-q2-2018-07-27", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-intra-cellular-therapies-inc-2018-07-25", "https://www.nasdaq.com/articles/roches-tecentriq-gets-breakthrough-therapy-status-for-hcc-2018-07-18", "https://www.nasdaq.com/articles/after-hours-most-active-jul-10-2018-cuz-kkr-glpi-twtr-mrvl-fdc-qqq-pfe-intc-bac-exel-vc", "https://www.nasdaq.com/articles/after-hours-most-active-jun-29-2018-cprt-exel-dps-cmcsa-twtr-upl-ge-qqq-symc-exc-bac-gm", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-06-28", "https://www.nasdaq.com/articles/exelixis-exel-jumps%3A-stock-rises-8-2018-06-27", "https://www.nasdaq.com/articles/3-top-mid-cap-stocks-buy-right-now-2018-08-01", "https://www.nasdaq.com/articles/asco-conference-preview-heres-what-biotech-investors-need-watch-2018-05-31", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-july-20th-2018-05-23", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-fda-gives-nod-to-amgens-drugs-eu-approves-exelixis-cabometyx-2018", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-05-19", "https://www.nasdaq.com/articles/exelixis-cabometyx-gets-eu-nod-for-first-line-kidney-cancer-2018-05-17", "https://www.nasdaq.com/articles/heres-why-you-should-sell-fresenius-medical-fms-stock-now-2018-05-14", "https://www.nasdaq.com/articles/radius-health-rdus-incurs-narrower-than-expected-q1-loss-2018-05-11", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-immunogen-inc-2018-06-26", "https://www.nasdaq.com/articles/asco-conference-preview-heres-what-biotech-investors-need-watch-2018-05-31", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-july-20th-2018-05-23", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-marine-products-nutrisystem-exelixis-illumina-and", "https://www.nasdaq.com/articles/3-healthcare-stocks-growing-over-100-2018-05-11", "https://www.nasdaq.com/articles/trump-announces-plan-reign-drug-prices-and-pharma-stocks-rally-2018-05-11", "https://www.nasdaq.com/articles/bull-day-exelixis-exel-2018-05-11", "https://www.nasdaq.com/articles/exelixis-applied-optoelectronics-and-nvidia-as-zacks-bull-and-bear-of-the-day-2018-05-11", "https://www.nasdaq.com/articles/heres-why-you-should-invest-in-intuitive-surgical-right-now-2018-05-10", "https://www.nasdaq.com/articles/5-winning-stocks-superb-efficiency-level-2018-05-10", "https://www.nasdaq.com/articles/pre-market-most-active-may-10-2018-nbr-roku-bp-tvix-qqq-wfc-hear-aeg-chl-exel-nvda-ing", "https://www.nasdaq.com/articles/why-booking-holdings-exelixis-and-l-brands-slumped-today-2018-05-10", "https://www.nasdaq.com/articles/hospital-product-sales-drive-mallinckrodt-mnk-q1-earnings-2018-05-10", "https://www.nasdaq.com/articles/valeant-vrx-rallies-earnings-beat-q1-raises-view-2018-05-10", "https://www.nasdaq.com/articles/why-exelixis-dropped-today-2018-05-10", "https://www.nasdaq.com/articles/dow-moves-back-black-2018-2018-05-11", "https://www.nasdaq.com/articles/heres-why-you-should-invest-in-intuitive-surgical-right-now-2018-05-10", "https://www.nasdaq.com/articles/5-winning-stocks-superb-efficiency-level-2018-05-10", "https://www.nasdaq.com/articles/pre-market-most-active-may-10-2018-nbr-roku-bp-tvix-qqq-wfc-hear-aeg-chl-exel-nvda-ing", "https://www.nasdaq.com/articles/intercept-icpt-q1-loss-narrower-than-expected-sales-lag-2018-05-08", "https://www.nasdaq.com/articles/exelixis-reaccelerates-growth-2018-05-04", "https://www.nasdaq.com/articles/notable-friday-option-activity-gild-exel-rig-2018-05-04", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings-sales-top-on-cabometyx-strength-2018-05-03", "https://www.nasdaq.com/articles/xiaflex-sterile-injectables-drive-endos-endp-q1-earnings-2018-05-10", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q1-loss-wider-than-expected-2018-05-09", "https://www.nasdaq.com/articles/prothena-prta-q1-loss-wider-than-expected-sales-miss-2018-05-09", "https://www.nasdaq.com/articles/why-exelixis-stock-broke-down-march-2018-04-12", "https://www.nasdaq.com/articles/exelixis-exel-in-focus%3A-stock-moves-7.7-higher-2018-04-11", "https://www.nasdaq.com/articles/after-hours-most-active-apr-10-2018-cmcsa-kmi-ip-qqq-czr-hrb-paa-yext-bx-intc-exel-akrx", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-exelixis-inc.-exel-2018-04-06", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-novartis-ag-2018-04-06", "https://www.nasdaq.com/articles/exelixis-exel-q1-2018-earnings-conference-call-transcript-2018-05-03", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-exelixis-exel-in-q1-earnings-2018-04-30", "https://www.nasdaq.com/articles/calitheras-kidney-cancer-candidate-gets-fast-track-status-2018-04-19", "https://www.nasdaq.com/articles/why-exelixis-stock-broke-down-march-2018-04-12", "https://www.nasdaq.com/articles/commit-purchase-exelixis-13-earn-112-using-options-2018-03-14", "https://www.nasdaq.com/articles/after-hours-most-active-mar-14-2018-qqq-fold-f-msft-qep-gm-usmc-ben-cmcsa-bsx-cnp-exel", "https://www.nasdaq.com/articles/why-exelixis-fell-149-february-2018-03-13", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-april-2018-04-04", "https://www.nasdaq.com/articles/weakness-seen-in-exelixis-exel-estimates%3A-should-you-stay-away-2018-04-04", "https://www.nasdaq.com/articles/why-is-exelixis-exel-down-17.2-since-its-last-earnings-report-2018-03-28", "https://www.nasdaq.com/articles/exelixis-cabometyx-gets-positive-chmp-opinion-in-europe-2018-03-26", "https://www.nasdaq.com/articles/rsi-alert-exelixis-exel-now-oversold-2018-03-23", "https://www.nasdaq.com/articles/commit-purchase-exelixis-13-earn-112-using-options-2018-03-14", "https://www.nasdaq.com/articles/3-stocks-watch-tuesday-exelixis-inc-exel-howard-hughes-corp-hhc-and-palo-alto-networks-inc", "https://www.nasdaq.com/articles/exelixis-becomes-oversold-2018-03-01", "https://www.nasdaq.com/articles/exelixis-breaks-below-200-day-moving-average-notable-exel-2018-02-28", "https://www.nasdaq.com/articles/perrigo-prgo-postpones-q4-earnings-results-shares-down-2018-02-27", "https://www.nasdaq.com/articles/exelixis-exel-q4-earnings-meet-estimates-revenues-beat-2018-02-27", "https://www.nasdaq.com/articles/health-care-sector-update-02272018-mnk-iart-amrn-prgo-exel-2018-02-27", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-wider-than-estimated-loss-in-q4-2018-02-27", "https://www.nasdaq.com/articles/5-things-exelixis-inc-management-wants-you-know-about-biotechs-future-2018-02-27", "https://www.nasdaq.com/articles/3-stocks-watch-tuesday-exelixis-inc-exel-howard-hughes-corp-hhc-and-palo-alto-networks-inc", "https://www.nasdaq.com/articles/exelixis-becomes-oversold-2018-03-01", "https://www.nasdaq.com/articles/exelixis-exel-q4-earnings-meet-estimates-revenues-beat-revised-2018-02-27", "https://www.nasdaq.com/articles/exelixis-inc-exel-q4-2017-earnings-conference-call-transcript-2018-02-26", "https://www.nasdaq.com/articles/key-factors-to-influence-penumbras-pen-earnings-in-q4-2018-02-21", "https://www.nasdaq.com/articles/whats-in-store-for-veeva-systems-veev-in-q4-earnings-2018-02-21", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-inogen-ingn-this-earnings-season-2018-02-21", "https://www.nasdaq.com/articles/whats-in-store-for-juno-therapeutics-juno-in-q4-earnings-2018-02-20", "https://www.nasdaq.com/articles/medicines-company-mdco-reports-q4-loss-revenues-slump-y-y-2018-02-22", "https://www.nasdaq.com/articles/what-to-expect-from-biomarin-bmrn-this-earnings-season-2018-02-20", "https://www.nasdaq.com/articles/whats-in-the-cards-for-geron-gern-this-earnings-season-2018-02-20", "https://www.nasdaq.com/articles/novartis-psoriasis-drug-cosentyx-positive-in-scalp-study-2018-02-20", "https://www.nasdaq.com/articles/will-acadia-acad-disappoint-investors-in-q4-earnings-2018-02-20", "https://www.nasdaq.com/articles/whats-in-store-for-ligand-lgnd-this-earnings-season-2018-02-19", "https://www.nasdaq.com/articles/abbvie-presents-new-data-on-upadacitinib-for-crohns-disease-2018-02-19", "https://www.nasdaq.com/articles/celgene-reports-positive-data-on-dermatology-drug-otezla-2018-02-19", "https://www.nasdaq.com/articles/can-pbm-unit-drive-express-scripts-esrx-earnings-in-q4-2018-02-20", "https://www.nasdaq.com/articles/roche-rhhby-to-acquire-flatiron-health-for-%241.9-billion-2018-02-16", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-bristol-myers-squibb-2018-02-16", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q4-earnings-sales-gives-2018-view-2018-02-15", "https://www.nasdaq.com/articles/agios-agio-q4-loss-wider-than-expected-revenues-slump-y-y-2018-02-15", "https://www.nasdaq.com/articles/prothenas-prta-loss-narrows-in-q4-pipeline-progresses-2018-02-15", "https://www.nasdaq.com/articles/shire-shpg-q4-earnings-beat-immunology-franchise-strong-2018-02-15", "https://www.nasdaq.com/articles/intercept-icpt-q4-earnings-sales-lag-on-dull-ocaliva-2018-02-15", "https://www.nasdaq.com/articles/acorda-acor-q4-earnings-miss-estimates-revenues-beat-2018-02-16", "https://www.nasdaq.com/articles/can-cvg-boost-medtronics-mdt-q3-earnings-once-again-2018-02-14", "https://www.nasdaq.com/articles/roches-rituxan-gets-priority-review-for-label-expansion-2018-02-14", "https://www.nasdaq.com/articles/aveo-aveo-to-get-%242-million-from-eusa-pharma-for-fotivda-2018-02-14", "https://www.nasdaq.com/articles/exelixis-reports-positive-data-from-thyroid-carcinoma-trial-2018-02-14", "https://www.nasdaq.com/articles/vertexs-third-cystic-fibrosis-treatment-gets-fda-approval-2018-02-13", "https://www.nasdaq.com/articles/intercept-starts-oca-trial-for-nash-patients-with-cirrhosis-2018-02-13", "https://www.nasdaq.com/articles/alkermes-alks-beats-q4-earnings-revenue-estimates-2018-02-15", "https://www.nasdaq.com/articles/can-jakafi-performance-drive-incytes-incy-q4-earnings-2018-02-12", "https://www.nasdaq.com/articles/will-ocaliva-sales-dampen-intercepts-icpt-q4-earnings-2018-02-12", "https://www.nasdaq.com/articles/fda-okays-jjs-prostate-cancer-drug-in-first-line-setting-2018-02-09", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2018-02-09", "https://www.nasdaq.com/articles/alnylams-alny-q4-earnings-and-revenues-top-estimates-2018-02-09", "https://www.nasdaq.com/articles/zoetis-zts-warming-up-to-q4-earnings%3A-whats-in-store-2018-02-09", "https://www.nasdaq.com/articles/will-prothena-prta-disappoint-investors-in-q4-earnings-2018-02-09", "https://www.nasdaq.com/articles/shire-shpg-to-report-q4-earnings%3A-whats-in-the-cards-2018-02-12", "https://www.nasdaq.com/articles/theravance-jj-ink-deal-for-inflammatory-intestinal-drug-2018-02-08", "https://www.nasdaq.com/articles/alexions-alxn-earnings-and-sales-beat-estimates-in-q4-2018-02-08", "https://www.nasdaq.com/articles/keryx-kerx-loss-wider-than-expected-in-q4-stock-down-2018-02-08", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-lululemon-exelixis-idexx-teradyne-and-pioneer", "https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-combo-positive-in-cancer-study-2018-02-06", "https://www.nasdaq.com/articles/spectrum-pharmas-rolontis-positive-in-pivotal-cancer-study-2018-02-06", "https://www.nasdaq.com/articles/pfizer-files-for-xtandi-in-early-stage-prostate-cancer-2018-02-06", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings-revenues-top-eylea-sales-grow-2018-02-08", "https://www.nasdaq.com/articles/5-best-efficient-stocks-your-portfolio-2018-02-06", "https://www.nasdaq.com/articles/5-biotech-stocks-set-to-trump-estimates-this-earnings-season-2018-02-06", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-immunogen-imgn-in-q4-earnings-2018-02-05", "https://www.nasdaq.com/articles/keryx-kerx-warming-up-to-q4-earnings%3A-whats-in-store-2018-02-05", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-02-05", "https://www.nasdaq.com/articles/strength-seen-in-alkermes-alks%3A-stock-soars-8.7-2018-02-05", "https://www.nasdaq.com/articles/allergans-anti-infective-drug-avycaz-receives-third-fda-nod-2018-02-02", "https://www.nasdaq.com/articles/roche-reports-positive-data-from-tecentriq-avastin-study-2018-02-06", "https://www.nasdaq.com/articles/alnylams-alny-rnai-candidates-nda-gets-priority-review-2018-02-02", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-glaxo-gsk-this-earnings-season-2018-02-02", "https://www.nasdaq.com/articles/gileads-gild-hcv-segment-to-decline-further-in-q4-earnings-2018-02-02", "https://www.nasdaq.com/articles/roche-rhhby-posts-solid-2017-sales-on-tecentriq-alecensa-2018-02-01", "https://www.nasdaq.com/articles/novo-nordisk-nvo-misses-q4-earnings-estimates-sales-beat-2018-02-01", "https://www.nasdaq.com/articles/amgen-gets-chmp-nod-to-add-endeavor-data-on-kyprolis-label-2018-01-31", "https://www.nasdaq.com/articles/puma-medison-team-up-to-commercialize-nerlynx-in-israel-2018-01-31", "https://www.nasdaq.com/articles/puma-canbridge-team-up-to-commercialize-nerlynx-in-china-2018-02-02", "https://www.nasdaq.com/articles/roche-gets-breakthrough-therapy-designation-for-asd-drug-2018-01-30", "https://www.nasdaq.com/articles/rough-start-busy-week-2018-01-30", "https://www.nasdaq.com/articles/vertex-vrtx-to-report-q4-earnings%3A-whats-in-the-cards-2018-01-29", "https://www.nasdaq.com/articles/glaxos-shingles-vaccine-shingrix-gets-positive-chmp-opinion-2018-01-29", "https://www.nasdaq.com/articles/quality-systems-qsii-q3-earnings-in-line-revenues-beat-2018-01-29", "https://www.nasdaq.com/articles/vertex-vrtx-stock-up-70-in-a-years-time%3A-heres-why-2018-01-25", "https://www.nasdaq.com/articles/whats-in-the-cards-for-gw-pharma-gwph-in-q1-earnings-2018-01-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-anthera-pharmaceuticals-bio-techne-exelixis-paratek-and", "https://www.nasdaq.com/articles/eu-unlikely-to-approve-pumas-nerlynx-in-2018-stock-down-2018-01-24", "https://www.nasdaq.com/articles/antheras-sollpura-strong-on-positive-futility-in-phase-iii-2018-01-23", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-gets-eu-nod-for-label-expansion-2018-01-23", "https://www.nasdaq.com/articles/regenerons-dupixent-receives-mhlw-nod-for-label-expansion-2018-01-23", "https://www.nasdaq.com/articles/biocryst-bcrx-idera-idra-announce-merger-shares-fall-2018-01-23", "https://www.nasdaq.com/articles/dr.-reddys-rdy-q3-earnings-fall-revenues-improve-y-y-2018-01-25", "https://www.nasdaq.com/articles/shire-gets-fda-nod-for-cinryze-tech-transfer-to-new-site-2018-01-25", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-exelixis-2018-01-23", "https://www.nasdaq.com/articles/bristol-myers-bmy-reports-data-from-checkmate-142-study-2018-01-22", "https://www.nasdaq.com/articles/these-2-developments-could-accelerate-johnson-johnsons-next-acquisition-2018-01-22", "https://www.nasdaq.com/articles/heres-why-agios-agio-stock-is-up-more-than-50-in-a-year-2018-01-19", "https://www.nasdaq.com/articles/beigene-bgne-surges%3A-stock-moves-12.6-higher-2018-01-19", "https://www.nasdaq.com/articles/biolinerx-cancer-drug-positive-as-monotherapy-in-phase-iia-2018-01-18", "https://www.nasdaq.com/articles/fancy-biotech-stocks-buyout-buzz-5-top-picks-2018-01-23", "https://www.nasdaq.com/articles/novo-nordisks-nvo-hits-52-week-high%3A-whats-driving-it-2018-01-17", "https://www.nasdaq.com/articles/exelixis-ipsen-report-positive-results-on-lead-cancer-drug-2018-01-17", "https://www.nasdaq.com/articles/why-biotech-stock-diving-despite-line-liver-cancer-results-2018-01-17", "https://www.nasdaq.com/articles/endo-endp-loses-35-in-a-year%3A-can-it-turn-around-in-2018-2018-01-16", "https://www.nasdaq.com/articles/novartis-nvs-announces-acceptance-of-humira-bla-by-the-fda-2018-01-16", "https://www.nasdaq.com/articles/glaxos-influenza-vaccine-gets-fda-nod-for-label-expansion-2018-01-15", "https://www.nasdaq.com/articles/prothena-prta-tumbles-18-in-a-year%3A-what-lies-ahead-2018-01-15", "https://www.nasdaq.com/articles/merck-strong-on-confirmatory-phase-iii-lung-cancer-study-2018-01-17", "https://www.nasdaq.com/articles/novo-nordisks-nvo-hits-52-week-high%3A-whats-driving-it-2018-01-17", "https://www.nasdaq.com/articles/exelixis-ipsen-report-positive-results-on-lead-cancer-drug-2018-01-17", "https://www.nasdaq.com/articles/why-biotech-stock-diving-despite-line-liver-cancer-results-2018-01-17", "https://www.nasdaq.com/articles/endo-endp-loses-35-in-a-year%3A-can-it-turn-around-in-2018-2018-01-16", "https://www.nasdaq.com/articles/novartis-nvs-announces-acceptance-of-humira-bla-by-the-fda-2018-01-16", "https://www.nasdaq.com/articles/glaxos-influenza-vaccine-gets-fda-nod-for-label-expansion-2018-01-15", "https://www.nasdaq.com/articles/prothena-prta-tumbles-18-in-a-year%3A-what-lies-ahead-2018-01-15", "https://www.nasdaq.com/articles/roche-ms-drug-ocrevus-gets-marketing-authorization-in-europe-2018-01-15", "https://www.nasdaq.com/articles/aradigms-bronchiectasis-candidate-has-negative-fda-vote-2018-01-12", "https://www.nasdaq.com/articles/perrigo-prgo-hits-52-week-high%3A-whats-driving-the-stock-2018-01-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-amgen-exelixis-alexion-and-vertex-2018-01-12", "https://www.nasdaq.com/articles/lillys-elanco-aratanas-veterinary-medicine-gets-eu-nod-2018-01-12", "https://www.nasdaq.com/articles/novo-nordisk-confirms-bid-for-ablynx-but-faces-rejection-2018-01-09", "https://www.nasdaq.com/articles/agenus-inc.-agen-jumps%3A-stock-rises-11.4-2018-01-09", "https://www.nasdaq.com/articles/emergent-down-on-18-view-posts-preliminary-17-results-2018-01-09", "https://www.nasdaq.com/articles/why-is-novo-nordisk-stock-up-more-than-50-in-past-year-2018-01-11", "https://www.nasdaq.com/articles/4-reasons-exelixis-inc-more-doubled-2017-2018-01-10", "https://www.nasdaq.com/articles/boston-scientific-rises-8.3-on-upbeat-4q-preliminary-sales-2018-01-10", "https://www.nasdaq.com/articles/masimo-gets-fda-nod-for-rad-97-enables-healthcare-at-home-2018-01-10", "https://www.nasdaq.com/articles/adamas-adms-launches-dyskinesia-drug-in-the-us-stock-up-2018-01-10", "https://www.nasdaq.com/articles/novo-nordisk-confirms-bid-for-ablynx-but-faces-rejection-2018-01-09", "https://www.nasdaq.com/articles/agenus-inc.-agen-jumps%3A-stock-rises-11.4-2018-01-09", "https://www.nasdaq.com/articles/emergent-down-on-18-view-posts-preliminary-17-results-2018-01-09", "https://www.nasdaq.com/articles/why-is-novo-nordisk-stock-up-more-than-50-in-past-year-2018-01-11", "https://www.nasdaq.com/articles/alnylam-sanofi-announce-restructuring-deal-for-rnai-products-2018-01-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-xoma-exelixis-emergent-biosolutions-and-medicines-2018", "https://www.nasdaq.com/articles/amgens-amgn-xgeva-gets-fda-approval-for-multiple-myeloma-2018-01-08", "https://www.nasdaq.com/articles/cancer-space-update%3A-new-regulatory-status-for-3-major-drugs-2018-01-05", "https://www.nasdaq.com/articles/emergent-starts-phase-ii-study-on-anti-influenza-candidate-2018-01-05", "https://www.nasdaq.com/articles/4-biotech-stocks-to-watch-in-the-new-year-2018-01-05", "https://www.nasdaq.com/articles/exelixis-amends-cabozantinib-tecentriq-phase-ib-trial-2018-01-05", "https://www.nasdaq.com/articles/acordas-shares-down-on-disappointing-ampyra-view-for-2018-2018-01-09", "https://www.nasdaq.com/articles/pfizer-pfe-collaborates-with-sangamo-for-gene-therapy-2018-01-04", "https://www.nasdaq.com/articles/secret-sauce-behind-exelixis-incs-12-move-higher-december-2018-01-04", "https://www.nasdaq.com/articles/inovio-amends-chinese-deal-for-immunotherapy-shares-up-2018-01-03", "https://www.nasdaq.com/articles/valeant-vrx-to-settle-allergan-litigation-for-%24290-million-2018-01-03", "https://www.nasdaq.com/articles/will-exelixis-exel-be-able-to-carry-17-momentum-in-2018-2017-12-28", "https://www.nasdaq.com/articles/8-stocks-buy-are-growing-faster-amazon-2017-12-28", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-exelixis-earns-93-rs-rating-2017-12-26", "https://www.nasdaq.com/articles/united-therapeutics-uthr-collaborates-with-corsair-pharma-2018-01-04", "https://www.nasdaq.com/articles/christmas-comes-early-these-5-biotechnology-stocks-2017-12-22", "https://www.nasdaq.com/articles/why-exelixis-inc-could-be-gold-mine-growth-investors-2017-12-21", "https://www.nasdaq.com/articles/exelixis-cabometyx-gets-fda-nod-for-first-line-kidney-cancer-2017-12-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-label-expansion-exelixiss-cabometyx-fda-nod-sparks-gene-therapy-2017", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-exelixis-earns-83-rs-rating-2017-12-20", "https://www.nasdaq.com/articles/exelixis-cabometyx-takes-aim-sutent-kidney-cancer-2017-12-20", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-bound-soar-higher-long-run-2017-12-12", "https://www.nasdaq.com/articles/if-i-could-only-buy-1-healthcare-stock-january-it-would-be-one-2017-12-22", "https://www.nasdaq.com/articles/christmas-comes-early-these-5-biotechnology-stocks-2017-12-22", "https://www.nasdaq.com/articles/why-exelixis-inc-could-be-gold-mine-growth-investors-2017-12-21", "https://www.nasdaq.com/articles/exelixis-cabometyx-gets-fda-nod-for-first-line-kidney-cancer-2017-12-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-label-expansion-exelixiss-cabometyx-fda-nod-sparks-gene-therapy-2017", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-exelixis-earns-83-rs-rating-2017-12-20", "https://www.nasdaq.com/articles/exelixis-cabometyx-takes-aim-sutent-kidney-cancer-2017-12-20", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-bound-soar-higher-long-run-2017-12-12", "https://www.nasdaq.com/articles/if-i-could-only-buy-1-healthcare-stock-january-it-would-be-one-2017-12-22", "https://www.nasdaq.com/articles/christmas-comes-early-these-5-biotechnology-stocks-2017-12-22", "https://www.nasdaq.com/articles/endo-endp-earnings-revenues-beat-in-q3-generics-weak-2017-11-10", "https://www.nasdaq.com/articles/perrigo-prgo-q3-earnings-top-2017-view-raised-shares-up-2017-11-09", "https://www.nasdaq.com/articles/merrimack-mack-q3-loss-narrower-than-expected-stock-up-2017-11-09", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q3-revenues-lag-estimates-2017-11-09", "https://www.nasdaq.com/articles/catalyst-cprx-posts-narrower-than-expected-loss-in-q3-2017-11-09", "https://www.nasdaq.com/articles/vivus-vvus-q3-loss-narrows-qsymia-falters-shares-down-2017-11-09", "https://www.nasdaq.com/articles/biotech-industry-small-innovators-outflank-big-caps-blockbuster-drug-patent-cliff-looms", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q3-earnings-top-2017-view-cut-2017-11-08", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q3-earnings-sales-shares-up-2017-11-08", "https://www.nasdaq.com/articles/agenus-agen-reports-in-line-loss-in-q3-revenues-lag-2017-11-08", "https://www.nasdaq.com/articles/infinity-infi-q3-loss-narrower-than-expected-view-intact-2017-11-08", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-q3-loss-narrows-focus-on-fotivda-2017-11-08", "https://www.nasdaq.com/articles/geron-gern-q3-loss-narrower-than-expected-sales-miss-2017-11-02", "https://www.nasdaq.com/articles/achillion-achn-q3-loss-narrows-pipeline-expansion-in-focus-2017-11-03", "https://www.nasdaq.com/articles/3-reasons-behind-exelixis-stocks-big-bounce-2017-11-03", "https://www.nasdaq.com/articles/sucampo-scmp-beats-on-q3-earnings-revenues-ups-17-view-2017-11-02", "https://www.nasdaq.com/articles/intercept-icpt-q3-loss-narrower-than-expected-sales-beat-2017-11-02", "https://www.nasdaq.com/articles/clear-reason-exelixis-inc-rocketed-higher-much-10-2017-11-02", "https://www.nasdaq.com/articles/neurocrine-exelixis-juno-stocks-rocket-after-crushing-views-2017-11-01", "https://www.nasdaq.com/articles/acorda-acor-q3-earnings-lag-estimates-revenues-up-y-y-2017-11-01", "https://www.nasdaq.com/articles/if-celgene-buys-biotech-investors-should-win-big-time-2017-10-31", "https://www.nasdaq.com/articles/exelixis-exel-beats-q3-earnings-on-solid-cabometyx-sales-2017-11-02", "https://www.nasdaq.com/articles/add-pieces-fxh-could-be-worth-75-2017-10-27", "https://www.nasdaq.com/articles/whats-in-the-offing-for-exelixis-exel-in-q3-earnings-2017-10-27", "https://www.nasdaq.com/articles/bristol-myers-bmy-misses-on-q3-earnings-opdivo-in-focus-2017-10-26", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-now-2017-10-24", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-intra-cellular-therapies-inc-2017-10-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-exelixis-soars-priority-review-fda-panel-supports-spark-drug-2017-10", "https://www.nasdaq.com/articles/company-news-for-oct-17-2017-2017-10-17", "https://www.nasdaq.com/articles/shire-shpg-q3-earnings-beat-immunology-franchise-strong-2017-10-30", "https://www.nasdaq.com/articles/exelixis-exel-looks-good%3A-stock-adds-17.2-in-session-2017-10-17", "https://www.nasdaq.com/articles/why-exelixis-rebound-just-getting-started-2017-10-17", "https://www.nasdaq.com/articles/exelixis-earns-relative-strength-rating-upgrade-2017-10-17", "https://www.nasdaq.com/articles/health-care-sector-update-10162017-ampeexeltgtx-2017-10-16", "https://www.nasdaq.com/articles/mid-day-market-update-transenterix-climbs-following-fda-clearance-senhance-surgical-robot", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-charles-schwab-earnings-top-views-2017-10-16", "https://www.nasdaq.com/articles/exelixis-rockets-17-year-high-kidney-liver-cancer-news-2017-10-16", "https://www.nasdaq.com/articles/fda-grants-priority-review-for-exelixis-rcc-drug-cabomteyx-2017-10-17", "https://www.nasdaq.com/articles/exelixis-exel-looks-good%3A-stock-adds-17.2-in-session-2017-10-17", "https://www.nasdaq.com/articles/why-exelixis-rebound-just-getting-started-2017-10-17", "https://www.nasdaq.com/articles/exelixis-earns-relative-strength-rating-upgrade-2017-10-17", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-pdp-2017-10-16", "https://www.nasdaq.com/articles/mondays-etf-movers-pdp-xrt-2017-10-16", "https://www.nasdaq.com/articles/rhenman-partners-asset-management-ab-buys-arena-pharmaceuticals-inc-vertex-2017-10-13", "https://www.nasdaq.com/articles/2-surprising-reasons-exelixis-inc-lost-17-september-2017-10-05", "https://www.nasdaq.com/articles/pre-market-most-active-oct-16-2017-f-exel-gsk-vale-nvo-bac-jd-mnkd-teva-aapl-mu-xt-2017-10", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-right-now-2017-10-02", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-immunogen-inc-2017-09-30", "https://www.nasdaq.com/articles/xbi-clvs-exel-srpt-large-outflows-detected-etf-2017-09-27", "https://www.nasdaq.com/articles/3-reasons-buy-dip-exelixis-2017-09-26", "https://www.nasdaq.com/articles/look-under-hood-fxh-has-10-upside-2017-09-26", "https://www.nasdaq.com/articles/relative-strength-alert-exelixis-2017-09-25", "https://www.nasdaq.com/articles/3-monster-biotech-stocks-making-2017-09-24", "https://www.nasdaq.com/articles/why-these-biotechs-are-leading-group-near-21-month-high-2017-10-04", "https://www.nasdaq.com/articles/why-exelixis-inc-slumped-today-2017-09-22", "https://www.nasdaq.com/articles/why-exelixis-wouldnt-be-warren-buffett-stock-2017-09-20", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2017-09-15", "https://www.nasdaq.com/articles/who-will-win-kidney-cancer-battle-between-bristol-myers-squibb-and-exelixis-2017-09-15", "https://www.nasdaq.com/articles/exelixis-inc-exel-president-and-ceo-michael-morrissey-sold-81-million-shares-2017-09-14", "https://www.nasdaq.com/articles/exelixis-inc-and-bristol-myers-squibb-co-gear-round-2-kidney-cancer-drug-battle-royale", "https://www.nasdaq.com/articles/why-exelixis-inc-could-be-gold-mine-growth-investors-2017-09-10", "https://www.nasdaq.com/articles/these-3-stocks-are-priced-perfection-can-they-deliver-2017-09-22", "https://www.nasdaq.com/articles/good-news-opdivo-shows-why-you-shouldnt-give-bristol-myers-squibb-stock-2017-09-08", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-juno-exel-acad-2017-09-06", "https://www.nasdaq.com/articles/can-exelixis-exel-run-higher-on-strong-earnings-estimate-revisions-2017-09-01", "https://www.nasdaq.com/articles/xbi-exel-alxn-vrtx-etf-inflow-alert-2017-08-30", "https://www.nasdaq.com/articles/can-buying-exelixis-stock-still-make-you-rich-2017-08-27", "https://www.nasdaq.com/articles/4-highest-growth-stocks-biotech-today-2017-08-24", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-exel-alxn-vrtx-2017-08-22", "https://www.nasdaq.com/articles/2-big-reasons-exelixis-inc-added-626-million-its-market-cap-august-2017-09-08", "https://www.nasdaq.com/articles/good-news-opdivo-shows-why-you-shouldnt-give-bristol-myers-squibb-stock-2017-09-08", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-juno-exel-acad-2017-09-06", "https://www.nasdaq.com/articles/can-exelixis-exel-run-higher-on-strong-earnings-estimate-revisions-2017-09-01", "https://www.nasdaq.com/articles/exelixis-inc-continued-its-winning-ways-and-rose-10-july-thanks-these-3-catalysts-2017-08", "https://www.nasdaq.com/articles/agenus-agen-q2-loss-narrower-than-expected-revenues-lag-2017-08-04", "https://www.nasdaq.com/articles/amag-pharma-amag-incurs-narrower-than-expected-loss-in-q2-2017-08-04", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-fxh-2017-08-21", "https://www.nasdaq.com/articles/exelixis-submits-snda-for-kidney-cancer-drug-cabometyx-2017-08-17", "https://www.nasdaq.com/articles/why-gilead-sciences-might-not-make-oncology-acquisition-2017-08-15", "https://www.nasdaq.com/articles/exelixis-exel-q2-earnings-sales-beat-on-cabometyx-sales-2017-08-03", "https://www.nasdaq.com/articles/3-reasons-still-buy-exelixis-stock-after-its-strong-q2-performance-2017-08-03", "https://www.nasdaq.com/articles/corcept-cort-q2-earnings-beat-estimates-guidance-raised-2017-08-02", "https://www.nasdaq.com/articles/intercept-icpt-posts-narrower-than-expected-loss-in-q2-2017-08-01", "https://www.nasdaq.com/articles/juno-therapeutics-juno-q2-loss-widens-revenues-surpass-2017-08-04", "https://www.nasdaq.com/articles/dr.-reddys-rdy-earnings-decline-y-y-in-q1-sales-rise-2017-07-31", "https://www.nasdaq.com/articles/immunogen-imgn-q2-loss-narrows-sales-cash-outlook-up-2017-07-31", "https://www.nasdaq.com/articles/keryx-kerx-posts-wider-than-expected-loss-in-q2-sales-beat-2017-07-28", "https://www.nasdaq.com/articles/alkermes-alks-q2-loss-narrower-than-expected-sales-beat-2017-07-28", "https://www.nasdaq.com/articles/acorda-acor-q2-earnings-miss-estimates-revenues-in-line-2017-07-28", "https://www.nasdaq.com/articles/celgene-celg-beats-q2-earnings-sales-estimates-ups-view-2017-07-27", "https://www.nasdaq.com/articles/glaxosmithkline-gsk-beats-on-q2-earnings-lowers-guidance-2017-07-27", "https://www.nasdaq.com/articles/commit-buy-exelixis-17-earn-115-using-options-2017-07-31", "https://www.nasdaq.com/articles/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-2017-07-27", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-etf-outflow-alert-2017-07-26", "https://www.nasdaq.com/articles/whats-in-the-cards-for-exelixis-exel-in-q2-earnings-2017-07-24", "https://www.nasdaq.com/articles/2-reasons-incyte-better-growth-stock-exelixis-and-1-reason-it-isnt-2017-07-21", "https://www.nasdaq.com/articles/pgx-pth-big-etf-inflows-2017-07-20", "https://www.nasdaq.com/articles/emergent-inks-agreement-to-acquire-anthrax-drug-raxibacumab-2017-07-20", "https://www.nasdaq.com/articles/vertex-vrtx-triple-combination-cf-studies-data-positive-2017-07-19", "https://www.nasdaq.com/articles/alexion-alxn-tops-q2-earnings-revenues-ups-2017-view-2017-07-27", "https://www.nasdaq.com/articles/gilead-gild-tops-q2-earnings-revenue-estimates-stock-up-2017-07-27", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-etf-outflow-alert-2017-07-26", "https://www.nasdaq.com/articles/whats-in-the-cards-for-exelixis-exel-in-q2-earnings-2017-07-24", "https://www.nasdaq.com/articles/2-reasons-incyte-better-growth-stock-exelixis-and-1-reason-it-isnt-2017-07-21", "https://www.nasdaq.com/articles/pgx-pth-big-etf-inflows-2017-07-20", "https://www.nasdaq.com/articles/exelixis-reaches-analyst-target-price-2017-07-13", "https://www.nasdaq.com/articles/valeant-vrx-to-sell-obagi-for-%24190-million-to-lower-debt-2017-07-19", "https://www.nasdaq.com/articles/why-are-shares-of-exelixis-exel-up-77-so-far-in-2017-2017-07-13", "https://www.nasdaq.com/articles/biodelivery-purdue-pharma-ink-marketing-deal-for-pain-drug-2017-07-13", "https://www.nasdaq.com/articles/arena-announces-secondary-stock-offering-of-150m-shares-2017-07-12", "https://www.nasdaq.com/articles/five-scorching-hot-stocks-screaming-higher-2017-07-11", "https://www.nasdaq.com/articles/exelixis-bristol-myers-initiate-trial-on-opdivo-cabometyx-2017-07-11", "https://www.nasdaq.com/articles/biotech-finds-its-stride-kidney-cancer-treatment-2017-07-07", "https://www.nasdaq.com/articles/cabosun-shone-exelixis-june-sending-its-shares-32-2017-07-07", "https://www.nasdaq.com/articles/why-exelixis-exel-could-be-an-impressive-growth-stock-2017-07-13", "https://www.nasdaq.com/articles/3-mid-cap-biotech-stocks-may-be-red-hot-takeover-candidates-2017-07-05", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-clvs-exel-alxn-2017-07-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-malibu-boats-addus-homecare-exelixis-gran-tierra-energy", "https://www.nasdaq.com/articles/best-stocks-second-half-2017-2017-07-03", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2017-06-27", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-june-27th-2017-06-27", "https://www.nasdaq.com/articles/aveos-kidney-cancer-candidate-gets-chmp-recommendation-2017-06-27", "https://www.nasdaq.com/articles/after-hours-most-active-jul-6-2017-wy-phm-oke-mrk-qqq-src-apc-ttwo-aapl-atvi-exel-csco", "https://www.nasdaq.com/articles/these-3-stocks-are-over-500-last-3-years-2017-06-25", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-novartis-ag-2017-06-24", "https://www.nasdaq.com/articles/roundtable-1-stock-i-brag-about-owning-2017-06-23", "https://www.nasdaq.com/articles/after-hours-most-active-jun-23-2017-exel-ebay-avp-fnb-grpn-bgcp-nrz-cvs-mu-esv-bmy-aapl", "https://www.nasdaq.com/articles/mid-day-market-update-red-hat-rises-after-strong-q1-results-circor-shares-slide-2017-06-21", "https://www.nasdaq.com/articles/aveo-reaches-enrollment-target-in-pivotal-tivozanib-study-2017-06-21", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-higher-carmax-tops-q1-expectations-2017-06-21", "https://www.nasdaq.com/articles/cara-therapeutics-cara-shows-strength%3A-stock-adds-12.2-in-session-2017-06-27", "https://www.nasdaq.com/articles/2-longs-and-2-shorts-watch-june-21-2017-06-21", "https://www.nasdaq.com/articles/exelixiss-cabometyx-positive-for-first-line-kidney-cancer-2017-06-20", "https://www.nasdaq.com/articles/why-exelixis-inc-zoomed-higher-today-2017-06-19", "https://www.nasdaq.com/articles/monday-sector-leaders-medical-instruments-supplies-biotechnology-stocks-2017-06-19", "https://www.nasdaq.com/articles/exelixis-initiates-cabozantinib-tecentriq-combination-trial-2017-06-13", "https://www.nasdaq.com/articles/2-reasons-exelixis-inc-shares-sank-16-may-2017-06-06", "https://www.nasdaq.com/articles/3-stocks-exelixis-return-potential-2017-06-05", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-acia-exel-ulta-2017-06-21", "https://www.nasdaq.com/articles/2-longs-and-2-shorts-watch-june-21-2017-06-21", "https://www.nasdaq.com/articles/exelixiss-cabometyx-positive-for-first-line-kidney-cancer-2017-06-20", "https://www.nasdaq.com/articles/why-exelixis-inc-zoomed-higher-today-2017-06-19", "https://www.nasdaq.com/articles/5-things-exelixis-inc-management-said-after-q1-earnings-blowout-youll-want-know-2017-05-02", "https://www.nasdaq.com/articles/five-breakout-zacks-rank-1-strong-buy-stocks-move-2017-05-02", "https://www.nasdaq.com/articles/play-potential-earnings-beat-with-these-5-top-ranked-stocks-2017-05-02", "https://www.nasdaq.com/articles/pfizers-kidney-cancer-drug-gets-acceptance-in-the-u.s.-eu-2017-06-02", "https://www.nasdaq.com/articles/whoa-operating-profit-exelixis-inc-2017-05-02", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-june-16th-2017-05-01", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-600-follow-through-indicator-75-sensitive-2017-05", "https://www.nasdaq.com/articles/5-things-bristol-myers-squibbs-management-wants-you-know-2017-04-29", "https://www.nasdaq.com/articles/apple-aapl-to-report-q2-earnings%3A-is-a-beat-in-store-2017-04-28", "https://www.nasdaq.com/articles/is-intercept-icpt-poised-for-a-beat-this-earnings-season-2017-04-28", "https://www.nasdaq.com/articles/what-to-expect-from-quotient-technology-quot-q1-earnings-2017-04-27", "https://www.nasdaq.com/articles/exelixis-exel-posts-earnings-in-q1-cabometyx-in-focus-2017-05-02", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings%3A-will-the-stock-disappoint-2017-04-25", "https://www.nasdaq.com/articles/meditor-group-ltd-buys-celldex-therapeutics-sells-vivus-2017-04-24", "https://www.nasdaq.com/articles/read-you-buy-biotech-stocks-2017-04-23", "https://www.nasdaq.com/articles/heres-why-best-yet-come-exelixis-inc-2017-04-20", "https://www.nasdaq.com/articles/xbi-vrtx-bivv-exel-large-inflows-detected-etf-2017-04-18", "https://www.nasdaq.com/articles/exelixis-inc-time-move-2017-04-18", "https://www.nasdaq.com/articles/3-stocks-turned-5000-more-18000-year-or-less-2017-04-12", "https://www.nasdaq.com/articles/insperity-nsp-q1-earnings%3A-is-a-surprise-in-the-cards-2017-04-27", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings%3A-will-the-stock-disappoint-2017-04-25", "https://www.nasdaq.com/articles/meditor-group-ltd-buys-celldex-therapeutics-sells-vivus-2017-04-24", "https://www.nasdaq.com/articles/read-you-buy-biotech-stocks-2017-04-23", "https://www.nasdaq.com/articles/heres-why-best-yet-come-exelixis-inc-2017-04-20", "https://www.nasdaq.com/articles/xbi-vrtx-bivv-exel-large-inflows-detected-etf-2017-04-18", "https://www.nasdaq.com/articles/exelixis-inc-time-move-2017-04-18", "https://www.nasdaq.com/articles/3-stocks-turned-5000-more-18000-year-or-less-2017-04-12", "https://www.nasdaq.com/articles/insperity-nsp-q1-earnings%3A-is-a-surprise-in-the-cards-2017-04-27", "https://www.nasdaq.com/articles/exelixis-exel-q1-earnings%3A-will-the-stock-disappoint-2017-04-25", "https://www.nasdaq.com/articles/meditor-group-ltd-buys-celldex-therapeutics-sells-vivus-2017-04-24", "https://www.nasdaq.com/articles/read-you-buy-biotech-stocks-2017-04-23", "https://www.nasdaq.com/articles/heres-why-best-yet-come-exelixis-inc-2017-04-20", "https://www.nasdaq.com/articles/xbi-vrtx-bivv-exel-large-inflows-detected-etf-2017-04-18", "https://www.nasdaq.com/articles/exelixis-inc-time-move-2017-04-18", "https://www.nasdaq.com/articles/3-horrible-stocks-retirees-2017-03-12", "https://www.nasdaq.com/articles/xlf-pth-big-etf-outflows-2017-04-11", "https://www.nasdaq.com/articles/if-you-love-exelixis-you-should-check-out-juno-therapeutics-2017-04-09", "https://www.nasdaq.com/articles/3-winning-stocks-you-never-saw-coming-2017-04-04", "https://www.nasdaq.com/articles/iwm-amd-exel-nrz-large-inflows-detected-etf-2017-03-20", "https://www.nasdaq.com/articles/why-exelixis-already-55-year-2017-03-15", "https://www.nasdaq.com/articles/3-most-important-numbers-exelixis-inc-2017-03-14", "https://www.nasdaq.com/articles/top-stocks-are-already-crushing-market-2017-2017-03-13", "https://www.nasdaq.com/articles/3-horrible-stocks-retirees-2017-03-12", "https://www.nasdaq.com/articles/xlf-pth-big-etf-outflows-2017-04-11", "https://www.nasdaq.com/articles/exelixis-balance-sheet-safe-2017-03-07", "https://www.nasdaq.com/articles/9-stocks-to-buy-that-are-growing-faster-than-amazon-2017-03-07", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-uwm-nrz-xpo-exel-2017-03-06", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-glaxosmithkline-celgene-and-exelixis-2017-03-02", "https://www.nasdaq.com/articles/exelixis-inc-turns-profit-dont-get-too-excited-2017-03-01", "https://www.nasdaq.com/articles/exelixis-exel-reports-q4-earnings-revenues-beat-y-y-2017-02-28", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-exelixis-u.s.-silica-holdings-intuit-and-rpc-2017-02-28", "https://www.nasdaq.com/articles/3-factors-drove-exelixis-inc-higher-19-february-2017-03-07", "https://www.nasdaq.com/articles/keryx-kerx-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-24", "https://www.nasdaq.com/articles/radius-health-rdus-posts-wider-loss-in-q4-2017-02-24", "https://www.nasdaq.com/articles/trimas-trs-to-post-q4-earnings%3A-whats-in-the-cards-2017-02-23", "https://www.nasdaq.com/articles/juno-therapeutics-juno-q4-earnings%3A-whats-in-the-cards-2017-02-23", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q4-earnings%3A-is-a-surprise-in-store-2017-02-23", "https://www.nasdaq.com/articles/endocyte-ecyt-to-post-q4-earnings%3A-whats-in-the-cards-2017-02-23", "https://www.nasdaq.com/articles/horizon-hznp-q4-earnings%3A-stock-likely-to-disappoint-2017-02-23", "https://www.nasdaq.com/articles/tenet-healthcare-thc-q4-earnings%3A-whats-in-the-cards-2017-02-24", "https://www.nasdaq.com/articles/endo-endp-to-post-q4-earnings%3A-will-the-stock-disappoint-2017-02-22", "https://www.nasdaq.com/articles/exelixis-exel-q4-earnings%3A-is-positive-surprise-in-store-2017-02-22", "https://www.nasdaq.com/articles/first-week-exel-april-21st-options-trading-2017-02-22", "https://www.nasdaq.com/articles/patterson-companies-pdco-q3-earnings%3A-whats-in-store-2017-02-21", "https://www.nasdaq.com/articles/intercept-icpt-to-post-q4-earnings%3A-whats-in-the-cards-2017-02-21", "https://www.nasdaq.com/articles/ionis-ions-q4-earnings%3A-whats-in-the-cards-for-the-stock-2017-02-21", "https://www.nasdaq.com/articles/acadia-pharma-acad-q4-earnings%3A-whats-in-store-this-time-2017-02-23", "https://www.nasdaq.com/articles/medtronic-mdt-q3-earnings%3A-disappointment-in-the-cards-2017-02-20", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-earnings%3A-will-it-post-a-beat-again-2017-02-17", "https://www.nasdaq.com/articles/merrimack-mack%3A-what-awaits-the-stock-in-q4-earnings-2017-02-17", "https://www.nasdaq.com/articles/radius-health-rdus-q4-earnings%3A-will-the-stock-disappoint-2017-02-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-celgene-fate-therapeutics-exelixis-and", "https://www.nasdaq.com/articles/forget-gilead-buy-these-5-biotech-stocks-instead-2017-02-13", "https://www.nasdaq.com/articles/5-drug-stocks-poised-beat-earnings-estimates-q4-2017-02-09", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-bristol-myers-squibb-2017-02-13", "https://www.nasdaq.com/articles/can-allscripts-mdrx-surprise-investors-in-q4-earnings-2017-02-10", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-exelixis-rpc-unit-and-fortress-transportation-and", "https://www.nasdaq.com/articles/exelixis-exel-shares-march-higher-can-it-continue-2017-02-10", "https://www.nasdaq.com/articles/can-nutrisystem-ntri-surprise-investors-in-q4-earnings-2017-02-09", "https://www.nasdaq.com/articles/ecolab-ecl%3A-whats-in-the-cards-this-earnings-season-2017-02-09", "https://www.nasdaq.com/articles/buy-4-stocks-riding-high-superb-earnings-acceleration-2017-02-09", "https://www.nasdaq.com/articles/5-drug-stocks-poised-beat-earnings-estimates-q4-2017-02-09", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-bristol-myers-squibb-2017-02-13", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-cellectis-s.a.-exelixis-exact-sciences-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-exelixis-ligand-pharmaceuticals-and-redhill", "https://www.nasdaq.com/articles/3-scorching-hot-biotech-stocks-are-they-buys-2017-02-08", "https://www.nasdaq.com/articles/4-stocks-watch-led-biotech-2017-02-08", "https://www.nasdaq.com/articles/4-drug-stocks-are-broker-favorites-2017-02-07", "https://www.nasdaq.com/articles/5-great-biotech-stocks-buy-now-2017-02-07", "https://www.nasdaq.com/articles/2-big-reasons-exelixis-inc-soared-22-january-2017-02-02", "https://www.nasdaq.com/articles/dentsply-xray-q4-earnings%3A-is-disappointment-in-store-2017-02-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-cellectis-s.a.-exelixis-exact-sciences-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-exelixis-ligand-pharmaceuticals-and-redhill", "https://www.nasdaq.com/articles/3-scorching-hot-biotech-stocks-are-they-buys-2017-02-08", "https://www.nasdaq.com/articles/4-stocks-watch-led-biotech-2017-02-08", "https://www.nasdaq.com/articles/4-drug-stocks-are-broker-favorites-2017-02-07", "https://www.nasdaq.com/articles/5-great-biotech-stocks-buy-now-2017-02-07", "https://www.nasdaq.com/articles/2-big-reasons-exelixis-inc-soared-22-january-2017-02-02", "https://www.nasdaq.com/articles/dentsply-xray-q4-earnings%3A-is-disappointment-in-store-2017-02-08", "https://www.nasdaq.com/articles/3-mid-cap-biotech-stocks-buy-february-2017-01-29", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-novartis-2017-01-23", "https://www.nasdaq.com/articles/4-momentum-charts-watch-week-2017-01-11", "https://www.nasdaq.com/articles/biotech-stocks-what-watch-2017-2016-12-29", "https://www.nasdaq.com/articles/3-biggest-risks-pfizer-2017-2016-12-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-colucid-pharmaceuticals-exelixis-tesaro-and-achaogen", "https://www.nasdaq.com/articles/better-buy-celldex-therapeutics-inc-vs-exelixis-2016-12-23", "https://www.nasdaq.com/articles/4-building-blocks-pushed-exelixis-inc-higher-164-2016-2017-01-05", "https://www.nasdaq.com/articles/exelixis-ipsen-amend-exclusive-agreement-for-cabometyx-2016-12-22", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-august-2017-2016-12-20", "https://www.nasdaq.com/articles/exelixis-stock-203-2016-there-still-more-upside-ahead-2016-12-20", "https://www.nasdaq.com/articles/7-top-stocks-were-excited-about-headed-2017-2016-12-19", "https://www.nasdaq.com/articles/forget-marijuana-stocks-buy-these-3-biotech-stocks-instead-2016-12-18", "https://www.nasdaq.com/articles/xt-exel-s-mrvl-large-inflows-detected-etf-2016-12-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-regeneron-pharmaceuticals-ophthotech-and", "https://www.nasdaq.com/articles/4-biotech-stocks-more-doubled-2016-2016-12-22", "https://www.nasdaq.com/articles/2-companies-i-wish-id-bought-2016-2016-12-12", "https://www.nasdaq.com/articles/heres-why-trumps-pledge-lower-drug-prices-all-bark-and-no-bite-2016-12-12", "https://www.nasdaq.com/articles/wednesdays-etf-movers-gdxj-xbi-2016-12-07", "https://www.nasdaq.com/articles/wednesday-sector-laggards-drugs-biotechnology-stocks-2016-12-07", "https://www.nasdaq.com/articles/mid-day-market-update-dave-busters-climbs-upbeat-results-sigma-designs-shares-slide-2016", "https://www.nasdaq.com/articles/sanofi-sny-soliqua-approved-for-type-2-diabetes-in-adults-2016-11-22", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2016-12-01", "https://www.nasdaq.com/articles/5-top-performing-biotechnology-stocks-of-november-2016-12-01", "https://www.nasdaq.com/articles/7-a-rated-healthcare-stocks-to-buy-before-trump-takes-office-2016-11-18", "https://www.nasdaq.com/articles/shire-launches-cuvitru-in-u.s.-for-primary-immunodeficiency-2016-11-17", "https://www.nasdaq.com/articles/3-things-exelixis-must-do-survive-and-thrive-2017-2016-11-17", "https://www.nasdaq.com/articles/3-stocks-add-your-portfolio-biotech-ma-hopes-rise-2016-11-17", "https://www.nasdaq.com/articles/bristol-myers-enterome-ink-immuno-oncology-collaboration-2016-11-17", "https://www.nasdaq.com/articles/new-oriental-education-technology-group-bjs-restaurants-ariad-pharmaceuticals-incyte-and", "https://www.nasdaq.com/articles/endo-reports-positive-cellulite-treatment-data-on-xiaflex-2016-11-18", "https://www.nasdaq.com/articles/exelixis-best-small-cap-biotech-stock-2016-11-18", "https://www.nasdaq.com/articles/7-a-rated-healthcare-stocks-to-buy-before-trump-takes-office-2016-11-18", "https://www.nasdaq.com/articles/shire-launches-cuvitru-in-u.s.-for-primary-immunodeficiency-2016-11-17", "https://www.nasdaq.com/articles/3-things-exelixis-must-do-survive-and-thrive-2017-2016-11-17", "https://www.nasdaq.com/articles/3-stocks-add-your-portfolio-biotech-ma-hopes-rise-2016-11-17", "https://www.nasdaq.com/articles/bristol-myers-enterome-ink-immuno-oncology-collaboration-2016-11-17", "https://www.nasdaq.com/articles/new-oriental-education-technology-group-bjs-restaurants-ariad-pharmaceuticals-incyte-and", "https://www.nasdaq.com/articles/ionis-ions-offers-positive-interim-data-on-lipid-candidate-2016-11-16", "https://www.nasdaq.com/articles/pfizer-reports-phase-iii-psoriatic-arthritis-data-on-xeljanz-2016-11-16", "https://www.nasdaq.com/articles/celldex-stock-up-on-positive-data-on-new-cancer-candidate-2016-11-15", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-11", "https://www.nasdaq.com/articles/catalyst-cprx-reports-narrower-than-expected-loss-in-q3-2016-11-10", "https://www.nasdaq.com/articles/mylan-myl-q3-earnings-revenues-miss-on-epipen-woes-2016-11-10", "https://www.nasdaq.com/articles/vivus-vvus-reports-narrower-than-expected-loss-in-q3-2016-11-12", "https://www.nasdaq.com/articles/election-2016s-healthcare-winners-and-losers-2016-11-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-enzo-biochem-exelixis-genmab-a-s-heska-and-incyte-2016", "https://www.nasdaq.com/articles/endo-endp-q3-earnings-revenues-beat-view-intact-2016-11-08", "https://www.nasdaq.com/articles/wright-medical-wmgi-q3-loss-narrower-than-expected-2016-11-08", "https://www.nasdaq.com/articles/arena-arna-q3-loss-lower-than-expected-revenues-rise-2016-11-08", "https://www.nasdaq.com/articles/horizon-hznp-stock-up-despite-q3-earnings-revenue-miss-2016-11-08", "https://www.nasdaq.com/articles/conatus-cnat-reports-narrower-than-expected-loss-in-q3-2016-11-09", "https://www.nasdaq.com/articles/pacific-biosciences-pacb-q3-loss-narrower-than-expected-2016-11-07", "https://www.nasdaq.com/articles/masimo-masi-beats-on-q3-earnings-revenues-guides-up-2016-11-07", "https://www.nasdaq.com/articles/exelixis-inc-continues-its-solid-launch-2016-11-07", "https://www.nasdaq.com/articles/why-were-excited-about-these-5-top-stocks-2016-11-05", "https://www.nasdaq.com/articles/dentsply-xray-beats-on-earnings-in-q3-misses-revenue-2016-11-04", "https://www.nasdaq.com/articles/intercept-icpt-q3-loss-narrower-than-expected-sales-miss-2016-11-04", "https://www.nasdaq.com/articles/aegerion-aegr-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/2-reasons-exelixis-inc-dove-17-october-and-1-excuse-be-excited-2016-11-07", "https://www.nasdaq.com/articles/pacific-biosciences-pacb-q3-loss-narrower-than-expected-2016-11-07", "https://www.nasdaq.com/articles/geron-gern-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/radius-health-rdus-q3-loss-match-estimates-wider-y-y-2016-11-04", "https://www.nasdaq.com/articles/community-health-cyh-q3-loss-in-line-with-estimates-2016-11-04", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/why-exelixis-inc-reported-higher-today-2016-11-04", "https://www.nasdaq.com/articles/fridays-etf-movers-xbi-gdxj-2016-11-04", "https://www.nasdaq.com/articles/acadia-healthcare-achc-misses-q3-earnings-cuts-view-2016-11-04", "https://www.nasdaq.com/articles/aduro-adro-stock-down-on-wider-than-expected-q3-loss-2016-11-04", "https://www.nasdaq.com/articles/geron-gern-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/radius-health-rdus-q3-loss-match-estimates-wider-y-y-2016-11-04", "https://www.nasdaq.com/articles/4-medical-and-biotech-stocks-watch-2016-11-02", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q4-earnings-top-revenues-lag-2016-11-02", "https://www.nasdaq.com/articles/qlts-qlti-reports-in-line-q3-loss-merger-in-focus-2016-11-02", "https://www.nasdaq.com/articles/gilead-gild-misses-q3-earnings-estimates-retains-view-2016-11-02", "https://www.nasdaq.com/articles/aerie-aeri-q3-loss-wider-than-expected-pipeline-in-focus-2016-11-03", "https://www.nasdaq.com/articles/prothena-prta-reports-wider-than-expected-loss-in-q3-2016-11-02", "https://www.nasdaq.com/articles/shire-shpg-misses-q3-earnings-revenue-estimates-2016-11-02", "https://www.nasdaq.com/articles/drug-stocks-q3-earnings-roster-for-nov-3-icpt-exel-akrx-2016-11-02", "https://www.nasdaq.com/articles/novo-nordisk-nvo-tops-q3-earnings-revenues-up-y-y-2016-10-31", "https://www.nasdaq.com/articles/immunogen-imgn-reports-wider-than-expected-loss-2016-10-31", "https://www.nasdaq.com/articles/exelixis-exel-q3-earnings%3A-whats-in-store-for-the-stock-2016-10-31", "https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-in-line-revenues-lag-estimates-2016-10-28", "https://www.nasdaq.com/articles/zoetis-zts-tops-q3-earnings-estimates-updates-outlook-2016-11-02", "https://www.nasdaq.com/articles/prothena-prta-reports-wider-than-expected-loss-in-q3-2016-11-02", "https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-incurs-narrower-y-y-loss-in-q3-2016-10-28", "https://www.nasdaq.com/articles/mckesson-mck-misses-on-q2-earnings-sales-cuts-view-2016-10-28", "https://www.nasdaq.com/articles/celgene-celg-beats-on-q3-earnings-raises-16-outlook-2016-10-27", "https://www.nasdaq.com/articles/the-medicines-co.-mdco-q3-loss-narrower-than-expected-2016-10-27", "https://www.nasdaq.com/articles/cardinal-health-cah-q1-earnings%3A-disappointment-in-store-2016-10-26", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-incyte-legacytexas-financial-group-exelixis-bayerische", "https://www.nasdaq.com/articles/biomarin-bmrn-q3-loss-narrows-y-y-pipeline-in-focus-2016-10-28", "https://www.nasdaq.com/articles/vertexs-vrtx-q3-loss-wider-than-expected-sales-miss-2016-10-26", "https://www.nasdaq.com/articles/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-2016-10-25", "https://www.nasdaq.com/articles/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-2016-10-25", "https://www.nasdaq.com/articles/5-profitable-stocks-for-outstanding-returns-2016-10-25", "https://www.nasdaq.com/articles/aduro-stock-down-on-partial-clinical-hold-on-ladd-studies-2016-10-25", "https://www.nasdaq.com/articles/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-2016-10-25", "https://www.nasdaq.com/articles/whats-in-store-for-stryker-syk-this-earnings-season-2016-10-25", "https://www.nasdaq.com/articles/express-scripts-esrx-q3-earnings-in-line-revenues-lag-2016-10-26", "https://www.nasdaq.com/articles/vertexs-vrtx-q3-loss-wider-than-expected-sales-miss-2016-10-26", "https://www.nasdaq.com/articles/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-2016-10-25", "https://www.nasdaq.com/articles/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-2016-10-25", "https://www.nasdaq.com/articles/5-profitable-stocks-for-outstanding-returns-2016-10-25", "https://www.nasdaq.com/articles/aduro-stock-down-on-partial-clinical-hold-on-ladd-studies-2016-10-25", "https://www.nasdaq.com/articles/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-2016-10-25", "https://www.nasdaq.com/articles/whats-in-store-for-merit-medical-mmsi-in-q3-earnings-2016-10-25", "https://www.nasdaq.com/articles/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-2016-10-25", "https://www.nasdaq.com/articles/can-nutrisystem-ntri-surprise-investors-in-q3-earnings-2016-10-24", "https://www.nasdaq.com/articles/bristol-myerss-bmy-opdivo-under-priority-review-by-fda-2016-10-24", "https://www.nasdaq.com/articles/merck-gets-fda-approval-for-investigational-drug-zinplava-2016-10-24", "https://www.nasdaq.com/articles/united-health-uhs%3A-whats-in-store-this-earnings-season-2016-10-24", "https://www.nasdaq.com/articles/varian-medical-var-q4-earnings%3A-whats-in-the-cards-2016-10-24", "https://www.nasdaq.com/articles/c.r.-bard-bcr-to-report-q3-earnings%3A-whats-in-the-cards-2016-10-24", "https://www.nasdaq.com/articles/whats-in-store-for-merit-medical-mmsi-in-q3-earnings-2016-10-25", "https://www.nasdaq.com/articles/xbis-underlying-holdings-could-mean-43-gain-potential-2016-10-21", "https://www.nasdaq.com/articles/alkermes-depression-candidate-positive-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/alexion-graft-versus-host-disease-drug-wins-orphan-status-2016-10-20", "https://www.nasdaq.com/articles/mercks-antiviral-medicine-meets-endpoint-in-phase-iii-2016-10-20", "https://www.nasdaq.com/articles/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-2016-10-20", "https://www.nasdaq.com/articles/astrazenecas-hyperkalemia-drug-nda-resubmission-accepted-2016-10-19", "https://www.nasdaq.com/articles/whats-in-store-for-athenahealth-athn-in-q3-earnings-2016-10-19", "https://www.nasdaq.com/articles/amgens-amgn-xgeva-meets-endpoint-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/xbis-underlying-holdings-could-mean-43-gain-potential-2016-10-21", "https://www.nasdaq.com/articles/alkermes-depression-candidate-positive-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/alexion-graft-versus-host-disease-drug-wins-orphan-status-2016-10-20", "https://www.nasdaq.com/articles/mercks-antiviral-medicine-meets-endpoint-in-phase-iii-2016-10-20", "https://www.nasdaq.com/articles/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-2016-10-20", "https://www.nasdaq.com/articles/astrazenecas-hyperkalemia-drug-nda-resubmission-accepted-2016-10-19", "https://www.nasdaq.com/articles/whats-in-store-for-athenahealth-athn-in-q3-earnings-2016-10-19", "https://www.nasdaq.com/articles/amgens-amgn-xgeva-meets-endpoint-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/shire-cancer-drug-onivyde-receives-eu-marketing-approval-2016-10-19", "https://www.nasdaq.com/articles/41-billion-reasons-why-gilead-sciences-might-need-new-management-2016-10-19", "https://www.nasdaq.com/articles/jj-jnj-outshines-in-q3-earnings-on-strong-pharma-sales-2016-10-18", "https://www.nasdaq.com/articles/teva-trisenox-wins-chmp-nod-for-expanded-use-in-leukemia-2016-10-18", "https://www.nasdaq.com/articles/ptc-therapeutics-falls-on-fda-denial-of-dmd-drug-appeal-2016-10-18", "https://www.nasdaq.com/articles/shire-shpg-updates-vyvanse-label-with-new-efficacy-data-2016-10-18", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-january-2019-2016-10-17", "https://www.nasdaq.com/articles/the-medicines-co.-reports-positive-phase-ii-data-on-pcsk9si-2016-10-19", "https://www.nasdaq.com/articles/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-2016-10-17", "https://www.nasdaq.com/articles/allergan-agn-gains-rights-to-rtgel-from-urogen-pharma-2016-10-17", "https://www.nasdaq.com/articles/allergans-belkyra-gets-swedish-approval-for-double-chin-2016-10-17", "https://www.nasdaq.com/articles/natus-medical-baby-q3-earnings%3A-whats-in-the-cards-2016-10-17", "https://www.nasdaq.com/articles/enzo-biochem-enz-looks-good%3A-stock-adds-11-in-session-2016-10-17", "https://www.nasdaq.com/articles/pfizer-and-bristol-myers-squibb-could-face-big-threat-small-biotech-exelixis-2016-10-17", "https://www.nasdaq.com/articles/sunesis-submits-response-to-questions-on-leukemia-drug-2016-10-14", "https://www.nasdaq.com/articles/tetraphase-begins-phase-iii-dosing-of-antibiotic-candidate-2016-10-17", "https://www.nasdaq.com/articles/intuitive-surgical-isrg-q3-earnings%3A-whats-in-store-2016-10-14", "https://www.nasdaq.com/articles/amag-issues-encouraging-updates-on-makena-feraheme-2016-10-13", "https://www.nasdaq.com/articles/will-these-5-drug-stocks-be-big-winners-earnings-season-2016-10-13", "https://www.nasdaq.com/articles/exelixis-goes-it-2016-10-13", "https://www.nasdaq.com/articles/supernus-supn-reports-encouraging-data-from-adhd-study-2016-10-13", "https://www.nasdaq.com/articles/momenta-pharmaceuticals-mnta-jumps%3A-stock-up-12.7-2016-10-12", "https://www.nasdaq.com/articles/these-3-little-biotechs-just-scored-big-2016-10-11", "https://www.nasdaq.com/articles/oncogenex-cancer-drug-fails-in-phase-iii-study-stock-down-2016-10-14", "https://www.nasdaq.com/articles/these-2-big-catalysts-pushed-exelixis-inc-higher-15-september-2016-10-07", "https://www.nasdaq.com/articles/fex-fyx-big-etf-inflows-2016-10-07", "https://www.nasdaq.com/articles/fitbit-inc-fit-trapped-in-middle-of-several-extreme-opinions-2016-10-03", "https://www.nasdaq.com/articles/exelixis-reaches-analyst-target-price-2016-10-03", "https://www.nasdaq.com/articles/forget-celldex-therapeutics-inc-these-2-stocks-doubled-last-year-2016-10-03", "https://www.nasdaq.com/articles/goldman-sachs-group-inc-gs%3A-are-we-entering-the-next-recession-2016-09-30", "https://www.nasdaq.com/articles/total-system-services-inc-tss-lost-its-momentum-2016-09-30", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-roche-2016-10-08", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-rises-over-2-intra-cellular-therapies-shares-slide-2016-09", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-pepsico-beats-q3-expectations-2016-09-29", "https://www.nasdaq.com/articles/why-exelixis-inc-continued-its-downfall-today-2016-09-29", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-falls-over-200-points-catabasis-shares-spike-higher-2016", "https://www.nasdaq.com/articles/why-exelixis-inc-got-hammered-today-2016-09-28", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xop-xbi-2016-09-28", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-exelixis-exel-2016-09-26", "https://www.nasdaq.com/articles/exelixis-inc.-exel-crushed-on-cabonivo-drug-trial-results-2016-09-30", "https://www.nasdaq.com/articles/3-longs-and-1-short-watch-2016-09-20", "https://www.nasdaq.com/articles/3-reasons-momentum-stock-investors-will-love-exelixis-exel-2016-09-20", "https://www.nasdaq.com/articles/these-3-stocks-have-doubled-their-investors-money-2016-09-17", "https://www.nasdaq.com/articles/forget-novavax-buy-these-4-biotech-stocks-instead-2016-09-16", "https://www.nasdaq.com/articles/will-exelixis-exel-continue-to-surge-higher-2016-09-15", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-xop-2016-09-14", "https://www.nasdaq.com/articles/3-stocks-to-watch-wednesday%3A-monsanto-company-mon-herbalife-ltd.-hlf-and-exelixis-inc.", "https://www.nasdaq.com/articles/first-week-may-2017-options-trading-exelixis-exel-2016-09-21", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-expe-exel-jive-2016-08-04", "https://www.nasdaq.com/articles/breaking-down-exelixis-incs-drug-launch-2016-08-04", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-500-follow-through-indicator-46-sensitive-2016-08", "https://www.nasdaq.com/articles/first-look-exelixis-incs-rocket-ship-drug-2016-08-02", "https://www.nasdaq.com/articles/can-gw-pharmaceuticals-gwph-surprise-in-q3-earnings-2016-08-02", "https://www.nasdaq.com/articles/will-agios-agio-disappoint-estimates-in-q2-earnings-2016-08-02", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-aug-3%3A-zts-exel-more-2016-08-02", "https://www.nasdaq.com/articles/exelixis-exel-posts-narrower-loss-in-q2-beats-on-revenues-2016-08-04", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/merrimack-mack%3A-can-the-stock-surprise-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/conatus-cnat-may-surprise-in-q2-earnings%3A-stock-to-gain-2016-08-01", "https://www.nasdaq.com/articles/keryx-kerx-q2-earnings-preview%3A-will-the-stock-gain-2016-07-29", "https://www.nasdaq.com/articles/whats-in-store-for-prothena-prta-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/pfizer-pfe-likely-to-beat-earnings-in-q2-again-2016-07-29", "https://www.nasdaq.com/articles/whtas-in-store-for-endocyte-ecyt-this-earnings-season-2016-07-28", "https://www.nasdaq.com/articles/geron-gern-q2-earnings-whats-store-stock-2016-08-01", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/merrimack-mack%3A-can-the-stock-surprise-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/conatus-cnat-may-surprise-in-q2-earnings%3A-stock-to-gain-2016-08-01", "https://www.nasdaq.com/articles/keryx-kerx-q2-earnings-preview%3A-will-the-stock-gain-2016-07-29", "https://www.nasdaq.com/articles/whats-in-store-for-prothena-prta-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/heres-how-pfizers-protecting-its-kidney-cancer-drug-new-competitors-2016-07-10", "https://www.nasdaq.com/articles/mallinckrodt-mnk-q3-earnings%3A-will-the-stock-surprise-2016-07-27", "https://www.nasdaq.com/articles/after-hours-most-active-jul-1-2016-fbz-tvix-ge-bac-t-jpm-xiv-pfe-wfc-exel-aapl-msft-2016", "https://www.nasdaq.com/articles/after-hours-most-active-jun-30-2016-lnt-alb-eme-qqq-swx-mu-bac-te-yhoo-exel-iqnt-msft-2016", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-arcos-dorados-holdings-corcept-therapeutics-exelixis-hecla", "https://www.nasdaq.com/articles/explosive-stocks-under-10-2016-06-28", "https://www.nasdaq.com/articles/5-reasons-hate-biotech-stocks-2016-06-23", "https://www.nasdaq.com/articles/4-cancer-drug-developers-you-need-have-your-radar-year-2016-06-15", "https://www.nasdaq.com/articles/exelixis-inc-setting-new-standard-care-2016-06-08", "https://www.nasdaq.com/articles/reason-why-exelixis-skyrocketed-205-june-2016-07-08", "https://www.nasdaq.com/articles/exelixis-up-on-positive-kidney-cancer-data-on-cabometyx-2016-06-07", "https://www.nasdaq.com/articles/pre-market-most-active-jun-6-2016-tvix-rdsb-vblt-azn-chk-aria-fcx-exel-rio-bac-xiv-mpel", "https://www.nasdaq.com/articles/why-transocean-exelixis-and-cf-industries-jumped-today-2016-06-06", "https://www.nasdaq.com/articles/roche-presents-encouraging-data-on-actemra-and-tecentriq-2016-06-06", "https://www.nasdaq.com/articles/exelixis-inc-gets-some-asco-love-2016-06-06", "https://www.nasdaq.com/articles/exelixis-inc-rides-cabometyxs-coattails-big-gains-may-2016-06-03", "https://www.nasdaq.com/articles/these-2-billionaires-are-dumping-exelixis-stock-should-you-2016-05-31", "https://www.nasdaq.com/articles/exelixis-exel-shows-strength%3A-stock-moves-11.2-higher-2016-06-07", "https://www.nasdaq.com/articles/after-hours-most-active-may-26-2016-cl-qqq-emc-bac-aapl-exel-t-fcx-tvix-rad-foxa-mdlz-2016", "https://www.nasdaq.com/articles/exelixis-kidney-cancer-drug-cabometyx-positive-in-phase-ii-2016-05-24", "https://www.nasdaq.com/articles/exelixis-exel-worth-a-look%3A-stock-up-8.1-in-session-2016-05-16", "https://www.nasdaq.com/articles/exelixis-exel-reports-wider-than-expected-loss-in-q1-2016-05-05", "https://www.nasdaq.com/articles/2-big-reasons-why-shares-exelixis-inc-soared-15-april-2016-05-04", "https://www.nasdaq.com/articles/drug-stocks-reporting-mid-week-mrk-abc-endp-more-2016-05-03", "https://www.nasdaq.com/articles/exelixis-exel%3A-whats-ahead-for-the-stock-in-q1-earnings-2016-05-02", "https://www.nasdaq.com/articles/new-data-could-push-exelixis-cabometyx-over-1-billion-peak-annual-sales-2016-05-27", "https://www.nasdaq.com/articles/pre-market-most-active-apr-26-2016-srpt-bp-src-mu-tvix-aapl-fcx-bbl-cplp-bac-rdsb-exel", "https://www.nasdaq.com/articles/exelixis-incs-cabometyx-approved-let-kidney-cancer-battle-begin-2016-04-26", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-2-kkr-shares-slide-following-q1-results-2016-04", "https://www.nasdaq.com/articles/commit-purchase-exelixis-350-earn-223-annualized-using-options-2016-04-14", "https://www.nasdaq.com/articles/after-hours-most-active-apr-12-2016-fdc-qqq-pfe-hlt-vrx-lyg-wll-cy-rrd-brcd-exel-nvax-2016", "https://www.nasdaq.com/articles/ignore-exelixis-inc-here-are-3-better-stocks-2016-04-07", "https://www.nasdaq.com/articles/10-biotech-stocks-with-big-catalysts-coming-this-quarter-2016-03-31", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-roche-2016-04-27", "https://www.nasdaq.com/articles/exelixis-incs-ekg-stock-chart-hits-low-spot-2016-03-15", "https://www.nasdaq.com/articles/why-exelixis-stock-dropped-10-tuesday-2016-03-09", "https://www.nasdaq.com/articles/exelixis-inc-partnering-approval-2016-03-07", "https://www.nasdaq.com/articles/exelixis-inc-stock-was-throttled-february-heres-why-2016-03-06", "https://www.nasdaq.com/articles/3-healthcare-stocks-short-sellers-are-wrong-about-2016-03-05", "https://www.nasdaq.com/articles/exelixis-exel-shows-strength%3A-stock-moves-5.2-higher-2016-03-02", "https://www.nasdaq.com/articles/exelixis-finally-snags-licensing-partner-cometriq-2016-03-01", "https://www.nasdaq.com/articles/better-buy-exelixis-inc-vs-bristol-myers-squibb-2016-03-15", "https://www.nasdaq.com/articles/after-hours-most-active-feb-25-2016-wtw-hpe-nrf-pfe-khc-un-bac-mchi-xiv-qqq-exel-nvax-2016", "https://www.nasdaq.com/articles/whats-in-store-for-exelixis-exel-this-earnings-season-2016-02-25", "https://www.nasdaq.com/articles/forget-gilead-sciences-these-stocks-doubled-last-year-2016-02-03", "https://www.nasdaq.com/articles/exelixis-cabozantinib-positive-in-renal-cell-carcinoma-study-2016-02-02", "https://www.nasdaq.com/articles/emotional-investing-deflates-exelixis-inc-january-2016-02-02", "https://www.nasdaq.com/articles/why-exelixis-inc-rocketed-higher-friday-2016-01-29", "https://www.nasdaq.com/articles/exelixiss-cabozantinib-granted-priority-review-in-the-u.s.-2016-01-29", "https://www.nasdaq.com/articles/exelixis-loss-narrower-than-expected-cabozantinib-in-focus-2016-03-01", "https://www.nasdaq.com/articles/best-small-cap-stocks-2015-2016-01-12", "https://www.nasdaq.com/articles/1-george-soros-quote-keep-mind-2016-2016-01-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-amgen-ligand-pharmaceuticals-revance", "https://www.nasdaq.com/articles/5-biotech-stocks-doubled-2015-2016-01-07", "https://www.nasdaq.com/articles/exelixis-inc-nearly-quadrupled-2015-heres-why-2016-01-06", "https://www.nasdaq.com/articles/exelixis-reveals-data-on-cabozantinib-for-kidney-cancer-2016-01-05", "https://www.nasdaq.com/articles/top-5-best-performing-biotech-stocks-2015-2016-01-02", "https://www.nasdaq.com/articles/bristol-myers-squibb-new-chapter-and-beginning-sustained-growth-2016-01-15", "https://www.nasdaq.com/articles/best-biotech-stocks-2015-2015-12-28", "https://www.nasdaq.com/articles/exelixis-submits-rolling-nda-for-oncology-drug-in-the-u.s.-2015-12-28", "https://www.nasdaq.com/articles/3-biotech-stocks-under-5-could-explode-higher-2016-2015-12-27", "https://www.nasdaq.com/articles/2-healthcare-stocks-dominated-2015-2015-12-27", "https://www.nasdaq.com/articles/why-exelixis-inc-trading-higher-today-2015-12-23", "https://www.nasdaq.com/articles/best-exelixis-inc-headlines-2015-2015-12-22", "https://www.nasdaq.com/articles/monday-1214-insider-buying-report-wlh-exel-2015-12-14", "https://www.nasdaq.com/articles/these-3-companies-doubled-2015-2015-12-31", "https://www.nasdaq.com/articles/roche-exelixis-cotellic-zelboraf-combination-gets-ec-nod-2015-11-26", "https://www.nasdaq.com/articles/fda-approves-exelixis-incs-new-cancer-drug-2015-11-23", "https://www.nasdaq.com/articles/roche-exelixis-announce-positive-data-on-cotellic-zelboraf-2015-11-23", "https://www.nasdaq.com/articles/did-you-miss-these-top-stories-healthcare-2015-11-16", "https://www.nasdaq.com/articles/exelixis-inc-earnings-riding-meteor-2015-11-15", "https://www.nasdaq.com/articles/are-investors-nuts-be-short-these-stocks-2015-11-14", "https://www.nasdaq.com/articles/6-stocks-could-double-2016-2015-11-14", "https://www.nasdaq.com/articles/these-3-stocks-doubled-investors-money-year-2015-12-10", "https://www.nasdaq.com/articles/roche-exelixis-cotellic-zelboraf-combination-gets-ec-nod-2015-11-26", "https://www.nasdaq.com/articles/fda-approves-exelixis-incs-new-cancer-drug-2015-11-23", "https://www.nasdaq.com/articles/roche-exelixis-announce-positive-data-on-cotellic-zelboraf-2015-11-23", "https://www.nasdaq.com/articles/did-you-miss-these-top-stories-healthcare-2015-11-16", "https://www.nasdaq.com/articles/exelixis-inc-earnings-riding-meteor-2015-11-15", "https://www.nasdaq.com/articles/are-investors-nuts-be-short-these-stocks-2015-11-14", "https://www.nasdaq.com/articles/6-stocks-could-double-2016-2015-11-14", "https://www.nasdaq.com/articles/these-3-stocks-doubled-investors-money-year-2015-12-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-retrophin-exelixis-actelion-and-enzo", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-400-follow-through-indicator-35-sensitive-2015-11", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-10-2015-dox-kgc-htht-exel-ingn-nvgs-pnnt-opwr-arna", "https://www.nasdaq.com/articles/what-to-expect-from-exelixis-exel-this-earnings-season-2015-11-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon.com-lendingtree-dycom-industries-exelixis-and", "https://www.nasdaq.com/articles/5-stocks-that-doubled-in-2015-and-keep-going-up-2015-11-04", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-november-2015-11-01", "https://www.nasdaq.com/articles/why-exelixis-shares-declined-today-2015-11-11", "https://www.nasdaq.com/articles/agenus-q3-loss-wider-than-expected-pipeline-in-focus-2015-10-28", "https://www.nasdaq.com/articles/use-options-chance-buy-exel-43-discount-2015-10-27", "https://www.nasdaq.com/articles/exelixis-starts-cometriq-rolling-nda-filing-for-kidney-cancer-2015-10-23", "https://www.nasdaq.com/articles/interesting-exel-put-and-call-options-december-18th-2015-10-21", "https://www.nasdaq.com/articles/how-much-could-exelixis-really-be-worth-2015-10-09", "https://www.nasdaq.com/articles/roche-rhhby-reports-positive-data-on-skin-cancer-drugs-2015-10-08", "https://www.nasdaq.com/articles/pre-market-most-active-oct-6-2015-pmcs-fcau-azn-fcx-armh-ilmn-bhp-tvix-dd-aapl-exel-pbr", "https://www.nasdaq.com/articles/united-therapeutics-beats-q3-earnings-revenues-2015-10-28", "https://www.nasdaq.com/articles/exelixis-cancer-drug-gets-breakthrough-therapy-status-2015-08-25", "https://www.nasdaq.com/articles/3-small-cap-biopharma-stocks-id-never-short-2015-08-12", "https://www.nasdaq.com/articles/exelixis-posts-wider-than-expected-loss-focus-on-pipeline-2015-08-12", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-500-follow-through-indicator-34-sensitive-2015-08", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-11-2015-symc-csc-slw-fosl-mygn-pe-viav-exel-taho-epay", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-anac-exel-xon-2015-08-10", "https://www.nasdaq.com/articles/exelixis-up-on-swiss-approval-of-advanced-melanoma-drug-2015-08-28", "https://www.nasdaq.com/articles/heres-why-exelixis-stock-briefly-gained-10-today-2015-08-27", "https://www.nasdaq.com/articles/exelixis-cancer-drug-gets-breakthrough-therapy-status-2015-08-25", "https://www.nasdaq.com/articles/3-small-cap-biopharma-stocks-id-never-short-2015-08-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/what-to-expect-from-exelixis-exel-this-earnings-season-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/forget-biogen-buy-these-promising-biotech-stocks-instead-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/explains-exelixis-meteor-ic-rise-july-2015-08-05", "https://www.nasdaq.com/articles/exelixis-exel-shows-strength%3A-stock-adds-8.2-in-session-tale-of-the-tape-2015-08-05", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-july-26-august-1-2015-08-04", "https://www.nasdaq.com/articles/can-the-rally-in-exelixis-exel-shares-continue-tale-of-the-tape-2015-07-29", "https://www.nasdaq.com/articles/what-to-expect-from-exelixis-exel-this-earnings-season-revised-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/what-to-expect-from-exelixis-exel-this-earnings-season-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/forget-biogen-buy-these-promising-biotech-stocks-instead-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/explains-exelixis-meteor-ic-rise-july-2015-08-05", "https://www.nasdaq.com/articles/pre-market-most-active-jul-24-2015-exel-t-amzn-biib-itek-fb-stm-qqq-nok-un-alu-ci-2015-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-exelixis-regeneron-five-prime-therapeutics-and", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-pcsk9-inhibitor-first-gain-approval-exelixis-positive-data", "https://www.nasdaq.com/articles/after-hours-most-active-jul-22-2015-qcom-exel-qqq-aa-wfm-rti-rf-bac-acwi-emc-exc-fnbc-2015", "https://www.nasdaq.com/articles/pre-market-most-active-jul-21-2015-nmr-pypl-vz-fb-aapl-abx-nok-gpro-phg-pkx-qqq-exel-2015", "https://www.nasdaq.com/articles/potential-kidney-cancer-drugs-could-revolutionize-treatment-2015-07-21", "https://www.nasdaq.com/articles/exelixis-meteoric-rise-on-positive-kidney-cancer-study-data-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-flat-morgan-stanley-beats-q2-views-2015-07-20", "https://www.nasdaq.com/articles/5-stocks-leading-xbi-biotech-etf-higher-etf-news-and-commentary-2015-06-25", "https://www.nasdaq.com/articles/can-the-rally-in-exelixis-exel-shares-continue-tale-of-the-tape-2015-06-25", "https://www.nasdaq.com/articles/exelixis-inc.-exel-in-focus%3A-stock-adds-7.5-in-session-tale-of-the-tape-2015-06-22", "https://www.nasdaq.com/articles/2-stocks-buy-now-biotech-2015-06-22", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-losing-money-wed-still-buy-them-2015-06-21", "https://www.nasdaq.com/articles/exelixis-roches-skin-cancer-drugs-fda-review-delayed-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/why-exelixis-inc-shares-slumped-today-2015-07-01", "https://www.nasdaq.com/articles/small-cap-stocks-watch-biotech-2015-06-30", "https://www.nasdaq.com/articles/5-stocks-leading-xbi-biotech-etf-higher-etf-news-and-commentary-2015-06-25", "https://www.nasdaq.com/articles/can-the-rally-in-exelixis-exel-shares-continue-tale-of-the-tape-2015-06-25", "https://www.nasdaq.com/articles/exelixis-inc.-exel-in-focus%3A-stock-adds-7.5-in-session-tale-of-the-tape-2015-06-22", "https://www.nasdaq.com/articles/2-stocks-buy-now-biotech-2015-06-22", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-losing-money-wed-still-buy-them-2015-06-21", "https://www.nasdaq.com/articles/exelixis-roches-skin-cancer-drugs-fda-review-delayed-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/financial-statement-analysis-3-metrics-all-healthcare-investors-need-know-2015-06-12", "https://www.nasdaq.com/articles/cancer-stocks-2-sell-1-buy-2015-06-10", "https://www.nasdaq.com/articles/how-1-sentence-caused-exelixis-inc-soar-may-2015-06-02", "https://www.nasdaq.com/articles/why-exelixis-incs-stock-briefly-spiked-today-2015-06-01", "https://www.nasdaq.com/articles/pre-market-most-active-jun-1-2015-onty-oran-altr-vblt-wfc-qqq-bmy-aapl-sfun-sto-c-exel", "https://www.nasdaq.com/articles/3-stocks-could-double-your-money-2015-05-30", "https://www.nasdaq.com/articles/biotech-investment-opportunities-long-term-2015-05-30", "https://www.nasdaq.com/articles/1-drug-will-make-or-break-these-3-biotech-stocks-2015-06-13", "https://www.nasdaq.com/articles/financial-statement-analysis-3-metrics-all-healthcare-investors-need-know-2015-06-12", "https://www.nasdaq.com/articles/youll-never-guess-why-exelixis-inc-romped-14-higher-2015-05-01", "https://www.nasdaq.com/articles/waiting-exelixis-incs-meteor-land-2015-05-01", "https://www.nasdaq.com/articles/will-endocyte-ecyt-disappoint-this-earnings-season-analyst-blog-2015-04-29", "https://www.nasdaq.com/articles/is-exelixis-exel-likely-to-report-narrower-loss-in-q1-analyst-blog-2015-04-29", "https://www.nasdaq.com/articles/3-biotech-stocks-may-disappear-2020-2015-04-15", "https://www.nasdaq.com/articles/will-epizyme-epzm-beat-estimates-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/3-soaring-biotech-stocks-under-10-are-they-buys-2015-04-22", "https://www.nasdaq.com/articles/exelixis-exel-shares-march-higher-can-it-continue-tale-of-the-tape-2015-04-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-rigel-pharmaceuticals-exelixis-and-atlas-resource", "https://www.nasdaq.com/articles/why-exelixis-exel-stock-might-be-a-great-pick-tale-of-the-tape-2015-04-20", "https://www.nasdaq.com/articles/best-pure-play-investment-cancer-drugs-2015-04-19", "https://www.nasdaq.com/articles/3-momentum-picks-under-%2410-to-sail-the-turbulent-market-analyst-blog-2015-04-17", "https://www.nasdaq.com/articles/2-speculative-biotechs-could-be-well-worth-risk-2015-04-14", "https://www.nasdaq.com/articles/after-hours-most-active-apr-14-2015-bac-intc-vale-qqq-mu-ge-brcd-igt-rf-crc-stld-exel-2015", "https://www.nasdaq.com/articles/exelixis-exel-shares-march-higher-can-it-continue-tale-of-the-tape-2015-02-27", "https://www.nasdaq.com/articles/looking-ahead-exelixis-inc-2015-02-25", "https://www.nasdaq.com/articles/will-exelixis-exel-miss-estimates-this-earnings-season-analyst-blog-2015-02-23", "https://www.nasdaq.com/articles/why-shares-exelixis-inc-briefly-spiked-higher-2015-02-19", "https://www.nasdaq.com/articles/pre-market-most-active-feb-19-2015-nok-wmt-ing-pbr-mt-tvix-aria-qqq-aapl-fb-exel-alu-2015", "https://www.nasdaq.com/articles/exelixis-exel-catches-eye%3A-stock-adds-15.9-in-session-tale-of-the-tape-2015-02-11", "https://www.nasdaq.com/articles/why-exelixis-inc-shares-skyrocketed-57-february-2015-03-03", "https://www.nasdaq.com/articles/xbi-fmi-exel-halo-large-inflows-detected-etf-2015-02-27", "https://www.nasdaq.com/articles/buying-biotech-purchasing-lottery-ticket-2015-02-08", "https://www.nasdaq.com/articles/why-exelixis-inc-shares-surged-higher-30-january-2015-02-05", "https://www.nasdaq.com/articles/why-shares-exelixis-inc-surged-2015-01-28", "https://www.nasdaq.com/articles/popular-beverage-could-be-responsible-20-reduction-melanoma-risk-2015-01-26", "https://www.nasdaq.com/articles/surprising-thing-most-2014s-top-10-stocks-have-common-2015-01-11", "https://www.nasdaq.com/articles/3-biotech-stocks-could-trounce-gilead-sciences-inc-2015-2015-01-07", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-ilf-2015-02-11", "https://www.nasdaq.com/articles/3-biotech-stocks-could-double-2015-2014-12-29", "https://www.nasdaq.com/articles/3-clinical-stage-biotech-stocks-should-be-your-watchlist-2015-2014-12-23", "https://www.nasdaq.com/articles/most-disappointing-clinical-failures-2014-2014-12-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-sophiris-cyclacel-plunge-data-chemocentryx-gains-positive-results", "https://www.nasdaq.com/articles/roche-submitted-nda-for-melanoma-combination-drug-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/3-healthcare-stocks-watch-2015-2014-12-15", "https://www.nasdaq.com/articles/exelixis-inc-stock-doomed-2014-12-02", "https://www.nasdaq.com/articles/does-drug-offer-exelixis-inc-investors-hope-future-2015-01-02", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-weatherford-sell-engineered-chemistry", "https://www.nasdaq.com/articles/mid-day-market-update-semiconductor-surges-1-billion-buyback-plan-pozen-shares-slip-2014", "https://www.nasdaq.com/articles/exelixis-cometriq-makes-comeback-2014-11-04", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-pushed-11-higher-october-2014-11-04", "https://www.nasdaq.com/articles/will-exelixis-exel-disappoint-this-earnings-season-analyst-blog-2014-11-03", "https://www.nasdaq.com/articles/exelixis-inc-stock-bad-news-buy-2014-10-13", "https://www.nasdaq.com/articles/3-biotech-stocks-near-52-week-lows-worth-buying-2014-10-08", "https://www.nasdaq.com/articles/exelixis-shares-down-on-comet-2-study-results-on-cabozantinib-analyst-blog-2014-12-02", "https://www.nasdaq.com/articles/exelixis-exel-is-in-oversold-territory%3A-whats-next-tale-of-the-tape-2014-10-03", "https://www.nasdaq.com/articles/big-news-these-5-stocks-esmo-2014-09-30", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-soaring-today-2014-09-29", "https://www.nasdaq.com/articles/why-exelixis-exel-stock-might-be-a-great-pick-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-crashed-70-2014-2014-09-13", "https://www.nasdaq.com/articles/exelixis-slumps-55-on-disappointing-cabozantinib-results-analyst-blog-2014-09-03", "https://www.nasdaq.com/articles/exelixis-exel-enters-oversold-territory-tale-of-the-tape-2014-09-03", "https://www.nasdaq.com/articles/roche-presents-data-on-cancer-immunotherapy-candidate-analyst-blog-2014-10-03", "https://www.nasdaq.com/articles/markets-mixed-conns-profit-misses-estimates-2014-09-02", "https://www.nasdaq.com/articles/us-stock-futures-barely-higher-output-spending-data-2014-09-02", "https://www.nasdaq.com/articles/us-futures-extend-gains-after-strong-august-manufacturing-data-seen-higher-2014-09-02", "https://www.nasdaq.com/articles/exelixis-incs-not-so-excellent-prostate-cancer-trial-results-2014-09-02", "https://www.nasdaq.com/articles/why-exelixis-inc-stock-plunged-2014-09-02", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-667-follow-through-indicator-32-sensitive-2014-07", "https://www.nasdaq.com/articles/exelixis-exel-jumps%3A-stock-adds-11.4-in-session-tale-of-the-tape-2014-07-25", "https://www.nasdaq.com/articles/exelixis-shares-slide-trial-results-norwegian-cruise-line-surges-2014-09-02", "https://www.nasdaq.com/articles/pre-market-most-active-jul-15-2014-jpm-bac-lo-vod-exel-alu-gpro-fb-kndi-oran-aapl-gs-2014", "https://www.nasdaq.com/articles/tuesdays-etf-movers-iyg-xbi-2014-07-15", "https://www.nasdaq.com/articles/harmonic-drops-weak-forecast-urs-shares-surge-2014-07-14", "https://www.nasdaq.com/articles/pre-market-most-active-jul-14-2014-c-urs-av-bac-abbv-myl-pgnx-aapl-gtat-alu-exel-qqq-2014", "https://www.nasdaq.com/articles/roche-presents-encouraging-data-on-cobimetinib-analyst-blog-2014-07-14", "https://www.nasdaq.com/articles/sector-update-health-care-2014-07-14-1", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-holding-small-gains-exelixis-rising-cancer-drug-progress", "https://www.nasdaq.com/articles/exelixis-exel-soars%3A-stock-adds-23-in-session-tale-of-the-tape-2014-07-15", "https://www.nasdaq.com/articles/mid-day-market-update-five-below-jumps-upbeat-results-exelixis-shares-decline-2014-03-26", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-francescas-issues-downbeat-q1-forecast-2014", "https://www.nasdaq.com/articles/pre-market-most-active-mar-26-2014-fcel-insm-bldp-siri-fb-exel-lyg-veev-bac-wft-pbr-nok", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-turn-red-dish-network-rises-2014-03-26", "https://www.nasdaq.com/articles/first-week-april-19th-options-trading-exelixis-exel-2014-02-26", "https://www.nasdaq.com/articles/exelixis-q4-loss-in-line-with-expectations-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/earnings-reaction-history-exelixis-inc-333-follow-through-indicator-34-sensitive-2014-02", "https://www.nasdaq.com/articles/exelixis-cometriq-approved-in-the-eu-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-01-23-0", "https://www.nasdaq.com/articles/after-hours-most-active-jan-22-2014-ebay-qqq-nflx-bac-exel-avp-aa-fcx-cole-msft-xom-gild", "https://www.nasdaq.com/articles/exelixis-exel-jumps%3A-stock-moves-11.1-higher-tale-of-the-tape-2014-01-07", "https://www.nasdaq.com/articles/oversold-etfs-looking-attractive-ihe-csd-psce-2013-12-17", "https://www.nasdaq.com/articles/10-stocks-watch-2014-2013-11-19", "https://www.nasdaq.com/articles/pre-market-most-active-nov-4-2013-bbry-alu-fb-tot-nok-gsk-aks-drys-jcp-qqq-vod-exel-2013", "https://www.nasdaq.com/articles/pre-market-most-active-nov-1-2013-t-abx-fb-ctl-aig-pcar-hot-alu-wdc-fslr-exel-mdlz-2013-11", "https://www.nasdaq.com/articles/sector-update-healthcare-stocks-lower-cbli-slides-42-abandoned-development-plans-2014-01", "https://www.nasdaq.com/articles/after-hours-most-active-oct-30-2013-fb-pbra-ben-qqq-expe-mcp-bac-mnkd-csco-exel-aa-hca", "https://www.nasdaq.com/articles/after-hours-most-active-oct-29-2013-atvi-nok-t-qqq-rad-renn-fb-ttwo-yelp-tibx-lnkd-exel", "https://www.nasdaq.com/articles/biotech-stocks-continue-recent-downtrend-ariad-tumbles-lowest-price-nearly-three-years", "https://www.nasdaq.com/articles/healthcare-stocks-higher-near-close-exelixis-climbs-new-52-week-high-after-starting-liver", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-10-1", "https://www.nasdaq.com/articles/trade-earnings-exelixis-inc-2013-08-06", "https://www.nasdaq.com/articles/after-hours-most-active-nov-1-2013-luk-smi-eric-qqq-arcp-eln-bbry-fb-dole-low-cole-exel", "https://www.nasdaq.com/articles/4-biotech-stocks-ready-explode-2012-09-06", "https://www.nasdaq.com/articles/after-hours-most-active-sep-4-2012-lyb-ht-shld-qqq-kgc-mtl-cvh-bac-exel-msft-fb-fran-2012", "https://www.nasdaq.com/articles/after-hours-most-active-aug-31-2012-qqq-mo-arr-mrk-bac-ctl-exel-nihd-esv-intc-siri-arna", "https://www.nasdaq.com/articles/pre-market-most-active-aug-9-2012-exel-rbn-nok-bac-csco-allya-siri-ahl-qqq-win-sph-mnst", "https://www.nasdaq.com/articles/time-decay-key-exelixis-strategy-2011-11-22", "https://www.nasdaq.com/articles/top-ten-undervalued-stocks-large-cash-cushions-2011-11-21", "https://www.nasdaq.com/articles/exelixis-setting-facts-straight-2011-11-07", "https://www.nasdaq.com/articles/pipeline-advances-at-exelixis-analyst-blog-2013-01-18", "https://www.nasdaq.com/articles/cancer-conference-trade-picking-biotech-bargains-2011-07-21", "https://www.nasdaq.com/articles/momentum-ideas-tuesdays-high-volume-gainers-2011-06-08", "https://www.nasdaq.com/articles/unusual-option-activity-halfway-point-2011-06-06", "https://www.nasdaq.com/articles/4-biotech-stocks-could-pop-2011-05-18", "https://www.nasdaq.com/articles/mid-day-update-stocks-firmly-lower-trade-deficit-japans-nuclear-situation-weigh-2011-04-12", "https://www.nasdaq.com/articles/us-indexes-broadly-lower-alcoa-earnings-trade-gap-weigh-stocks-2011-04-12", "https://www.nasdaq.com/articles/5-rallying-biotech-stocks-being-snapped-insiders-2011-02-24", "https://www.nasdaq.com/articles/bull-takes-large-dose-exelixis-2011-09-22", "https://www.nasdaq.com/articles/volatility-seller-returns-exelixis-2010-10-04", "https://www.nasdaq.com/articles/how-trade-callling-top-exelixis-2010-12-15"], "Content": []}